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PREFACE 
 
 
 Melanoma—a skin cancer arising from melanocytes—has been mentioned in 
medical texts dating back to Hippocrates in the 5th Century B.C. Although progress has been 
made in the field of melanoma biology, unfortunately, the overall death rates per 100,000 have 
remained relatively stable since 1975. Particularly, about half of melanoma patient tumors harbor 
an oncogenic mutation in the BRAF kinase and successfully achieving even, durable responses 
for patients remain a challenge. 
 In many cases, dysregulated cellular metabolism broadly affects therapy response by 
influencing compensatory signaling and expanding proliferation. Given many BRAF-mutated 
melanoma patients experience disease progression with targeted BRAF inhibitors, I hypothesized 
that therapeutic response is related to tumor metabolic phenotype, and that altering tumor 
metabolism could change therapeutic outcome. The work described in this dissertation addresses 
heterogeneous responses to targeted therapies in cell line models with respect to the tumor cell 
metabolism.  
 This dissertation attempts to discern the relationship of altered tumor cell 
metabolism and drug resistance, and the chapters are arranged to emphasize a linear course of 
response variability and assay development, glycolytic biology in relation to BRAF inhibition, 
and finer inspection of variability within a tumor. These findings help resolve discordant reports 
in the literature and link a targetable metabolic phenotype to cellular proliferation. Additionally, 
this work brings insight regarding the phenotypic roles of glycolysis and oxidative 
phosphorylation in BRAF-mutated melanomas. 
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CHAPTER I 
 
INTRODUCTION 
 
Melanoma Incidence, Prevalence, and Classification: 
Incidence and Prevalence 
Skin cancer is the most common cancer diagnosed in the US, although the true number of 
cases is difficult to estimate because the vast majority of skin cancers—basal and squamous cell 
carcinomas—are generally not reported in the national cancer registries because they are rarely 
fatal and considered curable (American	Cancer	Society,	Cancer	Facts	&	Figures	2017).  These 
non-melanoma skin cancers, also collectively called Keratinocyte Carcinoma or KC, were 
estimated to affect 3.3 million people in 2012 and comprise 5.4 million cases (this figure 
includes persons with multiple cases of KC, which is common) (American	Cancer	Society,	
Cancer	Facts	&	Figures	2017). Contrastingly, melanoma skin cancer, originating from 
melanocytes, constitutes approximately 1% of skin cancer cases but accounts for the majority of 
skin cancer deaths. The estimated number of new cases for the year of 2017 is 87,110 and the 
estimated number of deaths is 9,730 for that same year (American	Cancer	Society,	Cancer	Facts	
&	Figures	2017). In the state of Tennessee, an estimated 1,840 new cases and 250 deaths will 
occur for the year 2017 (American	Cancer	Society,	Cancer	Facts	&	Figures	2017).  Past data 
ranks the state of Tennessee at number 29 for age-adjusted death rates, but some neighboring 
states rank very high, like the state of Kentucky at number 6 (Howlader, Noone, et al., 2016). 
Melanoma has been mentioned in medical texts dating back to Hippocrates in the 5th Century 
B.C. (Rebecca, Sondak, and Smalley, 2012) and has been found in Inca mummies of Peru dating 
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back nearly 2,400 years (Urteaga and Pack, 1966). Incidence trends have continued to rise over 
the years, probably due to better detection methods, and changes in the population’s cancer risk 
factors—particularly older age and lifespan. Major risk factors include numerous (50+) moles, 
exposure to sun or UV radiation or tanning, family history of melanoma or other skin cancers, 
suppressed immune system, or increased sun sensitivity (excessive sunburns, blonde or red hair 
color) (American	Cancer	Society,	Cancer	Facts	&	Figures	2017). Melanoma continues to have a 
strong prevalence in both genders, and the projected percent new cases of melanoma for the year 
2017 are 6% and 4% for men and women, respectively (American	Cancer	Society,	Cancer	Facts	
&	Figures	2017). Broken down by stage at diagnosis, the 5-year survival rate across all races is 
98% in the localized stage, but drops to 62% and 16% if regional or distant metastases, 
respectively, are present (Siegel, Ma, et al., 2014). Unfortunately, the overall death rates per 
100,000 have remained relatively stable since 1975 (Howlader, Noone, et al., 2016).  
Classification and Molecular Landscape 
Melanoma has been historically managed surgically ever since the 1850s, particularly 
once surgical anesthesia became available and publications of surgical excision case reports 
appeared regularly in The Lancet (Rebecca, Sondak, and Smalley, 2012). In 1967, Wallace Clark 
published a scale to standardize and assess melanoma prognosis based upon histology: the extent 
of invasion into the epidermis and subcutaneous skin layers of dermis and fat (Clark, From, et 
al., 1969). This system of Clark levels (I-V, for melanoma in situ) would help guide surgical 
treatment and staging of melanoma for decades, and others like Alexander Breslow built upon 
this system to further demonstrate that tumor size and thickness played a considerable role in 
prognosis (Breslow, 1970). The mutational status and molecular landscape of melanoma has 
become of great importance in the last several years. Using multi-platform data (DNA, RNA, 
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and protein level) from one of the largest cohorts of clinically annotated patient samples ever 
collected, The Cancer Genome Atlas (TCGA) program cataloged the molecular landscape of 
melanoma and identified four genomic subtypes of melanoma: NRAS, BRAF, NF1, and Triple-
WT (Akbani, Akdemir, et al., 2015). These molecular subtypes are important indicators of 
prognosis and therapeutic options for patients with melanoma, and are generally mutually 
exclusive (i.e., patients harboring a NRAS mutation do not have a co-existing BRAF mutation, 
etc.). Approximately 50-60% of melanomas have a mutation in the BRAF kinase, generally an 
amino acid change of valine to glutamic acid at the 600 position, BRAFV600E (Davies, Bignell, et 
al., 2002; Ribas, Flaherty, et al., 2011; Ascierto, Kirkwood, et al., 2012). The patients harboring 
this mutation generally benefit from treatment regimens with small, targeted inhibitors of 
mutated-BRAF, such as vemurafenib or dabrafenib (Chapman, Hauschild, et al., 2011; Sosman, 
Kim, et al., 2012). Frustratingly, however, the response across the patients is highly variable and 
heterogeneous, despite the patients all harboring the same oncogenic lesion. A common, 
powerful endpoint of large clinical trials is the percent change in the largest target lesion; 
vemurafenib treatment provides confirmed objective responses in 48% of treatment-naïve 
patients (Chapman, Hauschild, et al., 2011) and an overall response rate of 53% in the metastatic 
setting (Sosman, Kim, et al., 2012).  Drug resistance to anti-BRAF therapy significantly 
contributes to patient deaths and investigating mechanisms of resistance is vital for broadening 
efficacy of anti-BRAF therapy. Thus, there remains a need to further examine mechanism of 
action and ultimate effect on cell behavior of anti-BRAF agents, and increase our understanding 
of the biochemical basis for resistance. Later in this chapter, mechanisms of resistance reported 
in the literature will be discussed in more detail.  Ultimately, heterogeneous responses can also 
be found in the cell line models used to study BRAF-mutated melanomas and data-mining in the 
	 4	
Cancer Cell Line Encyclopedia (CCLE) online data bank revealed a variable response to BRAF 
inhibitor PLX4720—similar to that found in patients (Figure 1.1). 
 
Figure 1.1: Heterogeneous Responses to BRAF Inhibition.  Plot of IC50 response of BRAF-
mutated melanoma cell lines in the CCLE. Cells were grown in either DMEM or RPMI1640 
media, plated at ~250 per well in 1,536 well plates; an 8 point dose curve was generated using 
concentrations starting at 8 µM, with 3.16 fold dilutions down. After 72 or 84 hours, Promega’s 
CellTiter-Glo (luciferase-based ATP assay) was used to count viable cells. All conditions were 
done with at least 2 replicates in the run; occasionally, some cell lines were run again/repeated. 
Due to the large nature of the repository and acquisition protocols, it is impossible to know 
which cell line/drug treatment combinations had which unique details (medium type, exact 
replicate numbers, plates runs, etc.)  
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Pathobiology of Mutated BRAF Kinase: 
Importance of Mutation Status 
The RAF oncogene was discovered more than 30 years ago and is an important integrator 
of signaling processes between receptor tyrosine kinases and downstream transcription factors 
(Rapp, Goldsborough, et al., 1983). The RAF homologues A, B, and C homo/hetero-dimerize 
and activate a cascade of signaling as part of the RAS-RAF-MEK-ERK axis. Thus, over-
activation of the homologue BRAF in melanoma can cause downstream signaling that 
inappropriately regulates cell proliferation, protein synthesis, metabolism, and migration. The 
RAF kinases generally signal as dimers, however, the mutation V600E (or, less commonly, 
V600D) makes the BRAF kinase constitutively active and mutated BRAF will signal as a 
monomer.  
The company Plexxikon marketed the first BRAF inhibitor, Zelboraf also known as 
vemurafenib or PLX4032. This compound, along with a research variant called PLX4720, is a 
heterocyclic, 7-aza-indole; PLX4032 differs in structure by the inclusion of 1 benzyl ring 
(compared to the PLX4720). The compounds also contain a difluoro-phenylsulfonamide 
structure that enriched and increased anti-BRAF activity (Tsai, Lee, et al., 2008).  Targeted 
BRAFi has a favorable short-term response in most patients, as demonstrated by significant 
reductions in FDG uptake following just 2 weeks of treatment with vemurafenib (Bollag, Hirth, 
et al., 2010). Interestingly, an up-regulation in MEK activation and tumor insensitivity is found 
with BRAFi and WT normal BRAF kinase, mostly attributed to a transactivation of the BRAF 
(Halaban, Zhang, et al., 2010; and Poulikakos, Zhang, et al., 2010). In the presence of active Ras 
signaling, binding of these ATP-competitive drugs in one RAF molecule of a dimer will induce 
an allosteric change that transactivates the other RAF molecule.  However, BRAF-mutated 
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melanomas have a sufficient low RAS activity that the potency of the ATP-competitive drugs is 
not tempered; thus, these inhibitors have select antitumor activity towards the melanoma cells 
and reduced clinical toxicity (Poulikakos and Rosen, 2011).  
 
Acquired Resistance To Therapies 
 There have been several mechanisms of acquired resistance to BRAF targeted therapy 
described in the literature. Collectively, these findings can be grouped into two categories: MEK-
dependent and MEK-independent pathway alterations. Figure 1.2 outlines many of the main 
mechanisms described, including BRAFV600E splice variants (Poulikakos, Persaud, et al., 2011), 
BRAF amplification (Shi, Moriceau, et al., 2012), BRAF kinase domain duplications (Kemper, 
Krijgsman, et al., 2016), mutations in MEK (Wagle, Van Allen, et al., 2014) and NRAS 
(Nazarin, Shi, et al., 2010), overexpression of COT (Johannessen, Boehm, et al., 2010), EGFR 
(Sun, Wang, et al., 2014), PDGFRb (Nazarin, Shi, et al., 2010) or CRAF (Montagut, Sharma, et 
al, 2008), and loss of negative regulators like NFI (Whittaker, Theurillat, et al., 2013). 
Amplification of the transcription factor MITF was reported by whole-exon sequencing of 
tumors treated with BRAF inhibitors (Van Allen, Wagle, et al., 2014) and Vergani et al. utilized 
MALDI-TOF to probe phosphotyrosine signaling and find cMET activation as a mediator of 
resistance (Vergani, Vallacchi, et al., 2011). Gatekeeper mutations in residues critical for ATP 
binding occurs frequently for other targeted therapies (for example, gefitinib against EGFR), but 
are virtually nonexistent in BRAF-mutated melanomas—despite the fact that gatekeeper 
mutations in the BRAFV600E kinase have been shown experimentally in cell lines to provide 
resistance to PLX4720 (Whittaker, Kirk, et al., 2010).  Additionally, Keiran Smalley’s group has 
demonstrated in cell line models that loss of PTEN will confer increased AKT signaling and 
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resistance to BRAF inhibition (Paraiso, Xiang, et al., 2011) and it has been correlated with 
increased brain metastases and decreased Overall Survival (OS) (Bucheit, Chen, et al., 2014). 
These data at a minimum highlight PTEN loss as a strong factor in regards to intrinsic resistance.  
 
 
Figure 1.2: Mechanisms of Resistance to BRAF Inhibition. In resistant BRAF-mutant 
melanomas MEK-independent and MEK-dependent alterations have been described in the 
literature. Mechanisms have been identified and validated in patient samples/tissues, and shown 
in clinical models such as cell lines. Figure structure is adapted and modified from educational 
material provided courtesy of Dr. Jeffrey Sosman in 2013.  
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Most of what we know about resistance to BRAF inhibitors comes from patient tumors or 
cell lines with acquired resistance, i.e., continued proliferation, growth or metastasis while under 
BRAF inhibitor therapy. Rizos and co-authors extensively examined therapeutic resistance in 
patients that progressed on vemurafenib or dabrafenib therapy. All of the patients had a 
progressing lesion (primary or metastatic) that was macro-dissected and analyzed for known 
progression-associated alterations by RT-PCR (for known mutated alleles and splice variants), 
gene expression microarray analysis (for known MAPK pathway activation signatures) and 
immunohistochemistry (protein staining of IGFR, pAKT, and PDGFRβ) (Rizos, Menzies, et al., 
2014).  Frustratingly, only 22 of 38 tumors (that had matched treatment-naïve tissue) could be 
mapped back to a known mechanism of resistance previously described in the literature (Rizos, 
Menzies, et al., 2014).  This large portion of unexplained resistance in approximately 42% of the 
tumor sampled after therapy failure highlights a major knowledge gap in the field. Others have 
commented on the dearth of knowledge regarding the cellular dynamics and biology leading up 
to observed BRAFi resistance (Smith, Brunton, et al., 2016) and this has fueled an explosion of 
research on non-genetic biology (such as cellular metabolism) in BRAF-mutated melanomas. 
 
Cellular Metabolism: 
Cellular metabolism is connected to an amazingly diverse set of biological processes 
including oogenesis (Sieber, Thomson, and Spradling, 2016), self-renewal of pluripotent stem 
cells (Zhang, Badur, et al., 2016), the cellular fate of immune T-cells (Buck, O’Sullivan, et al., 
2016), the tumor vasculature (Wenes, Shang, et al., 2016), and even the organ-specific site of 
cancer metastases (Dupuy, Tabaries, et al., 2015). Furthermore, cellular differentiation and 
epigenetics can change cellular metabolism and bioenergetics. Birket and coauthors’ elegantly 
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showed this in human embryonic stem cells (hESCs) and neuronal stem cells (NSCs): despite 
having similar relative distributions of ATP-consuming activities, the related secretion biology of 
hESCs accounts for a shift in not only global metabolism, but allocations of energetic demands 
(Birket, Orr, et al., 2010).  
 When oxygen is present and abundant, non-proliferating (usually differentiated) cells will 
catabolize glucose to pyruvate via glycolysis and then completely oxidize most of that pyruvate 
to CO2 in the mitochondria—a process called oxidative phosphorylation. Otto Warburg, a 
German physiologist, noted more than 90 years ago that cancer cells catabolized most glucose to 
lactate, regardless of the abundance of oxygen. Termed the Warburg Effect, he postulated that 
the mitochondria of tumor cells must be damaged because it is inefficient to rely on aerobic 
glycolysis (which nets 2 ATP molecules per glucose) as opposed to oxidative phosphorylation 
(which nets about 36 ATP molecules) (Warburg, 1956).  
The link between cancer and metabolism has been previously established; however, only 
recently has this reprogramming of metabolism or “deregulation of cellular energetics” been 
recognized as an emerging hallmark of cancer (Hanahan and Weinburg, 2011). Deregulated 
metabolism resonates with uncontrolled cellular proliferation: activating oncogenes have a 
propensity toward pushing cells into glycolytic metabolism, which supports fast proliferation 
(Vander Heiden, Cantley, and Thompson, 2009; DeBerardinis and Thompson, 2012). Fast 
proliferating cancer cells generally rely on aerobic glycolysis (the Warburg effect) despite the 
observation that the vast majority of glucose does not contribute to the biomass of cell; instead, 
the high glycolytic flux seems to be needed to provide energy and reducing equivalents, ATP and 
NAD+ respectively, and amino acids contribute the lions’ share to cellular biomass (Hosios, 
Hecht, et al., 2016). 
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 Historically, the field of cancer biology viewed Warburg’s glycolytic metabolism as a 
separate metabolic upshift that occurred exclusively within a cancer cell with no other concurrent 
metabolic programs directing or regulating cellular processes. However, this dualist framework 
of pitting Warburg glycolysis against particularly oxidative phosphorylation is problematic 
and—to borrow David Nicholls’ and Stuart Ferguson’s terminology—“bioenergetically 
dubious”. We now understand and appreciate that Warburg glycolysis and oxidative 
phosphorylation occur concurrently within a cell (Chi Dang, 2012) and, depending on the 
cellular context being studied, certain cancers may up regulate glycolysis, mitochondrial 
respiration or both. A perfect example of this phenomena is the Ski oncogene, and its 
bioenergetic effects as part of oncogenesis within a cell. The Ski oncogene is a transcriptional co-
factor whose interactions mediate a wide range of transcriptional programs, including TGF-β 
signaling (Chen, Lin, et al., 2009). Although it had been shown to promote oncogenesis, it was 
curious that chicken embryo fibroblasts (CEFs) overexpressing Ski did not appear to produce 
extra lactate and acidify the cell culture media as expected due to presumed Warburg glycolysis 
(Ye, Lemieux, et al., 2011). The authors went on to demonstrate that the Ski oncogene increased 
mitochondrial respiration in nearly every part of the electron transport chain (ETC) analyzed by 
high-resolution respirometry; the increases in oxygen consumption across the oxygraph trace 
support activity increases in virtually all ETC complexes (Ye, Lemieux, et al., 2011).  
The translational need for large-scale datasets has resulted in massive efforts to produce quality 
datasets that can be probed and analyzed across multiple platforms and biological processes. 
Large-scale profiling platforms were fundamental in the discovery of the best-studied examples 
of aberrant, metabolic re-wiring in cancer (Benjamin, Cravatt, and Nomura, 2012). Using stable 
isotope labeling of amino acids in cell culture (SILAC) as a large-scale proteomic platform, the 
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enzymatically-slow pyruvate kinase M2 isoform (PKM2) was found to shift metabolism of 
cancer cells to favor aerobic glycolysis and accumulate glycolytic intermediates for tumor 
growth (Christofk, Vander Heiden, et al., 2008).  Similarly, large-scale metabolite profiling via 
metabolic flux analysis led to the finding that citrate born of the TCA cycle, which is then 
converted to Acetyl-CoA once exported to the cytosol, is the primary building block of lipids and 
fatty acids (DeBerardinis, Mancuso, et al., 2007). Metabolomic profiling also led to the 
discovery of the first oncometabolite via mutant isocitrate dehydrogenase 1 (IDH1): 2-
hydroxyglutarate (Dang, White, et al., 2009). These examples are not cancer-specific in their 
origin, but more or less pathway and biochemistry centered. In cancer biology, large-scale 
genomics have taken prominence over phenotypic and functional platforms and this has probably 
limited the ability to find non-genetic sources of dysregulated metabolism driving cancer. 
Phenotype will likely precede the observance of genetic changes, therefore it is postulated that 
changes in cellular metabolism will be an early proximal marker for resistant phenotypes.  
 
Metabolic Strategies That Influence Therapeutic Response: 
Classic Routes of Tumor Drug Resistance Through Metabolism 
 Prevailing models of classic routes of tumor drug resistance have been historically linked 
to cellular metabolism. Zhao et al. summarize some of the major mechanisms of metabolic 
resistance to cancer agents (targeted or chemo-agents) in the broadest terms of accessibility for 
multiple cancer types. Figure 1.3 simplifies the mechanisms into 4 groups: 1) proliferation, 2) 
drug export, 3) pH regulation, and 4) signaling (Zhao, Butler, and Tan, 2013).  Glycolytic 
intermediates generated by dysregulated cancer metabolism fuel expanded cellular growth and 
contribute to clinical resistance. The ATP generated by the glycolytic breakdown of glucose 
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fuels the active export of chemotherapeutic agents by the ABC transporters (which are ATP-
dependent and consuming) and induces HIF1α expression. Export of the glycolytic end product, 
lactate and expression of carbonic anhydrases shift the pH ratio of the interior and exterior of the 
cell resulting in decreased passive transport of basic drugs. Signaling pathways activated by 
dysregulated metabolism also contribute to resistance, either via repressing pro-apoptotic 
signaling or activating compensatory pathways to circumvent drug-induced signal inhibition. 
 
Figure 1.3: Dysregulated Metabolism Can Affect Therapy Response. Dysregulated 
metabolism affects chemo-resistance via multiple cellular pathways. (Re-imagined and adapted 
from Zhao, Butler, and Tan, 2013) 
 
Cancer cells, in particular, exist in a “Metabolic Bubble” where stressors converge to 
present unique bioenergetics challenges. Traditionally, most cells must overcome three stress 
points: 1) biosynthetic stress (doubling mass for proliferation or macromolecule synthesis of 
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cytokines, factors, etc.); 2) reductive stress (maintaining NAD+ and FAD+ pools of reducing 
equivalents and cofactors for enzymatic reactions; and 3) energetic stress (ATP and GTP for 
normal cellular functions).  The distribution of NAD+ within a cell is very disparate: the nucleus 
has NAD+ concentration around ~70 µM, where as the mitochondria has estimates > 250 µM 
(Canto, Menzies, and Auwerx, et al., 2015). NAD+/NADH cannot diffuse through cell 
membranes to different biological compartments, thus the cell must maintain reducing equivalent 
levels within each cellular compartment via transfer of metabolic substrates and enzymatic 
salvage reactions.  
 
Metabolism in BRAF-mutated Melanomas: 
MITF and PGC1α 
Microphthalmia-associated transcription factor (MITF) has been under intense scrutiny in 
melanoma metabolism, due to the downstream signaling to Peroxisome proliferator-activated 
receptor Gamma Coactivator 1a (PGC1α) and subsequent mitochondrial biogenesis (Haq, 
Shoag, et al., 2013; and Vazquez, Lim, et al., 2013). Interestingly, Haq et al. demonstrated 
increased in vitro antitumor effect with the combination of PLX4720 and oligomycin, but the 
cell line used displayed an incredibly marked induction of PGC1α upon PLX4720 treatment—
unlike any of the other cell lines in their panel (Haq, Shoag, et al., 2013). Additionally, there 
exists a discrepancy between therapeutic doses of BRAF inhibitors and responses in BRAF-
mutated melanomas. When using PLX4720 at very low concentrations, MITF levels correlate 
with response, but at “IC50 doses” the correlation disappears (Calpaldo, Roller, et al., 2015). 
Thus, the level of MITF does not potentially explain non-responsive BRAF-mutated melanomas. 
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Presently, it is unknown whether BRAF-mutated melanomas all have constitutively high 
signaling across the MITF axis, if the signaling is fixed or permanent, or if there exists kinetic 
delays that render signaling defective for some melanomas. The interplay of transcription factors 
MITF and PGC1 and their role in mitochondrial biogenesis is a crucial topic in the field. 
Previously, the master metabolic regulator, AMP-activated Protein Kinase (AMPK), was thought 
to be a crucial component and effector of the MITF-PGC1a signaling axis.  AMPK is a 
heterotrimeric protein with three subunits (α, β and γ); the γ subunit binds and senses AMP levels 
and helps to promote phosphorylation on the catalytic α subunit (Hardie, 2007). pAMPK 
regulates a p53-dependent cell cycle checkpoint for energetically unfavorable conditions 
(DeBerardinis, Lum, et al., 2008; Hardie, 2004). So, it is quite possible to imagine that pAMPK 
is mediating cancer cell survival in some insensitive BRAF-muted melanomas. However, BRAF-
mutated melanomas have been shown to negatively regulate LKB1 through phosphorylation of 
S325 and S428 sites; BRAFV600E immuno-precipitates with AMPK. Zheng and colleagues 
showed ERK phosphorylates the LKB1, hindering its ability to activate the metabolic regulator 
AMPK (Zheng, Jeong, et al., 2009). This may be a mechanistic strategy for BRAF-mutated 
tumors to maintain and preserve strong MAPK pathway signaling: by negatively regulating 
LKB1, this could prevent AMPK from actively attenuating BRAF signaling through 
phosphorylation as shown in keratinocytes (Shen, Yuan, et al., 2013).  
Current Field of Melanoma Metabolism 
 The global, cellular metabolism of melanoma was somewhat poorly understood and 
studied until a bevy of articles appeared approximately 5 years ago. Researchers found 
melanoma cells to be excellent models to study the transcription factor MITF and one of its best-
known targets, PGC1a. Two back-to-back papers in the same issue of Cancer Cell demonstrate 
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the aberrant activation of PGC1a in a broad subset of melanoma cell lines (Vazquez, Lim, et al., 
2013) and the relationship of mutated BRAF signaling and oxidative phosphorylation (Haq, 
Shoag, et al., 2013). In particular, Haq et al. suggested that mutated BRAF likely regulates a 
robust oxphos program via MITF and PGC1a signaling, and this oxphos phenotype is increased 
upon treatment with the BRAF inhibitor PLX4720 (Haq, Shoag, et al., 2013). Interestingly, other 
researchers have postulated that mutated BRAF signaling regulates a glycolysis program crucial 
to these cells (Hall, Meyle, et al., 2013; and Parmenter, Kleinschmidt, et al., 2014). In fact, 
Parmenter et al.’s work provides the best evidence that inhibitors targeting the mutated BRAF 
functionally target glycolysis: lactate production, GLUT1 and GLUT3 protein expression on cell 
membranes, and uptake of [3H]2-Deoxy-Glucose (2DG) all are significantly higher in BRAF-
mutated melanomas versus WT-BRAF (Parmenter, Kleinschmidt, et al., 2014). Amazingly, 
matched trios of BRAFV600 melanoma patient biopsies before treatment, during early treatment 
(less than 22 days) and after treatment failure/progression showed statistically significant 
dynamics of hexokinase-2 (HK2) expression decreasing upon treatment then increasing back up 
after resistance (Parmenter, Kleinschmidt, et al., 2014). This discordance in our understanding of 
melanoma cellular metabolism is further highlighted by recent data from Meenhard Herlyn’s 
group: analysis of TCGA data revealed patients with the worst prognosis (overall survival) had 
tumor biopsies that highly expressed genes enriched in both glycolysis and oxidative 
phosphorylation (Zhang, Frederick, et al., 2016). 
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Summary and Purpose of Study: 
Summary 
Although considerable work has been done to investigate mechanisms of resistance in 
BRAF-mutated melanomas, the substantial portion of unexplained resistance to therapy 
(approximately 40%) amongst patients that progressed on targeted BRAFi therapy highlights a 
gap in our understanding of the biochemical basis of therapeutic resistance. As part of my 
project, I considered the possibility that the diversity of vemurafenib responses seen in patients 
was due to metabolic differences within their tumor cells, in spite of possessing the same driving 
oncogenic lesion of BRAFV600E or -V600D. The purpose of this study is to test the hypothesis that 
oncogene addicted tumor cells, such as BRAF mutated melanomas, respond to targeted therapy 
based on intrinsic cellular metabolism, and to test whether that cellular metabolic state is 
clinically targetable with FDA-approved drugs. Several tasks were identified to help achieve that 
goal and move this thesis project forward: 1) curating in vitro melanoma cell line models that 
exhibit therapeutic response variability in regards to proliferation; 2) refining and employing an 
assay to measure proliferation dynamics and catch subtleties missed by typical end point assays; 
and 3) mapping and assessing global metabolism and potential substrate utilization as part of 
cellular bioenergetics. For this work I aimed to create a suite of high-throughput experiments that 
would allow me to ascertain the bioenergetic landscape by looking at the tumor cells’ ability to 
proliferative under various metabolic stressors, and utilize substrates for glycolytic or oxidative 
phosphorylation processes. In the following chapters I show that we can overcome time-related 
biases and poor dynamical outputs of traditional IC50 assays (Chapter III), link glucose 
utilization with therapeutic response phenotypes (Chapter IV), suggest mitochondrial function 
and physiology as a biological indicator of response (Chapter V), and steer high-throughput 
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pipelines to find putative drug targets that may augment response in these cell line models 
(Chapter VI). Additionally, in Chapter VI, I present unpublished data that can help drive future 
experiments and research questions. Some of this data (like the reactive oxygen species (ROS) 
experiments) was completed early in the project in order to help eliminate and streamline the 
questions and project motivations. Other data (like the high-throughput screening (HTS) 
response data) are logical extensions of other completed manuscripts. At the time of writing this 
thesis, we are curating compounds for a targeted HTS of anti-retrovirals and other mitochondrial 
inhibitors; data on an interesting WNT inhibitor—pyrvinium pamoate—are shown in preliminary 
form. 
Project Motivations  
Although progress has been made in the field of melanoma biology, a finer understanding 
of the cellular metabolism is still needed. This is particularly highlighted again by the TCGA 
data presented by Zhang et al.: of the four subgroups (GlycHi/OxHi, GlycHi/OxLow, GlycLow/OxHi, 
GlycLow/OxLow) the best overall survival correlations had low Glycolysis gene signatures, but it is 
clear that only melanomas of a particular phenotype of glycolysis are super-sensitive and 
responsive to BRAF inhibition (Zhang, Frederick, et al., 2016). The metabolic activities of 
cancer cells make attractive targets of therapeutic intervention because they arise in concert with 
uncontrollable proliferation, oncogenic signaling, and therapeutic resistance. Thus, creating a 
thesis project that can add information about the unique metabolic biochemistry of BRAF-
mutated melanomas is desirable. Several goals and motivations of this project include: 1) to 
examine BRAF inhibition’s heterogeneous effect on tumor proliferation; 2) to discern the 
relationship of altered tumor cell metabolism and drug resistance, and possibly resolve some of 
the field’s discordant findings about BRAF-mutated melanoma cellular metabolism; and 3) 
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obtain multi-parametric metabolic data that could possibly classify or cluster subtypes of 
sensitive or insensitive melanomas. 
 
Research Questions 
 As stated earlier, the purpose of this study is to understand how BRAF-mutated 
melanomas respond to targeted therapy and manage to proliferate when deprived of the signaling 
induced by the oncogene those cell’s are addicted to. The larger, overarching research question 
that this project entails is: Can we manipulate the metabolism of BRAF-mutated melanomas 
and affect sensitivity or response to targeted therapies? Imbedded within this larger 
framework of questions includes other smaller aims to 1) study and characterize the variability in 
melanoma cell line models more closely, and 2) query the relationship between a cell’s 
metabolism and the cell’s response (in regards to proliferation) to BRAF inhibition. This 
approach of targeting differential tumor metabolism represents a break from previous models 
constrained within the narrow scopes of upstream and downstream the RAS-RAF-MEK-ERK 
signaling axis. The metabolic phenotypes should be independently actionable—regardless of the 
driving mutations upstream. Based on the recent flurry of melanoma metabolism papers, tackling 
the problem of heterogeneous responses through the lens of tumor metabolism puts the concepts 
and approach of this application on the leading edge.    
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CHAPTER II 
 
MATERIALS & METHODS 
 
Reproduced and adapted from:  Hardeman KN, Peng C, Paudel BB, Meyer CT, et al. (2017). 
“Dependence On Glycolysis Sensitizes BRAF-mutated Melanoma For Increased Response To 
BRAF Inhibition.” Scientific Reports 7; 42604. 
 
And:  Harris LA, Frick PL, Garbett SP, Hardeman KN, et al. (2016). “An Unbiased Metric Of 
Antiproliferative Drug Effect In Vitro.” Nature Methods 13, 497-500. 
 
And: Paudel BB, Harris LA, Hardeman KN, et al. “Dysfunctional Mitochondria Leads To A 
Non-quiescent Idling State In Drug Treated BRAF Mutated Melanoma Cells.” (In Preparation)  
 
Reagents: 
The BRAF inhibitor used in these studies, PLX4720 (catalog# S1152), was obtained from 
Selleckchem (Houston, TX) and solubilized in dimethyl sulfoxide (DMSO) at a stock 
concentration of 10 mM. BKM120 (Cat# S2247, Buparlisib) was obtained from Selleckchem 
(Houston, TX) and solubilized in DMSO at a stock concentration of 10 mM. Trametinib (Cat# T-
8123) and BEZ235 (Cat# N-4288) were obtained from LC Laboratories (Woburn, MA) and 
solubilized in DMSO at stock concentrations of 1 mM. Cisplatin (Cat# 479306, cis-
Diamineplatinum(II) dichlorine) was obtained from SigmaAldrich and solubilized in phosphate 
buffered saline (PBS) at a stock concentration of 12.5 mM. All drugs were aliquoted and stored 
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at -20°C until use except for cisplatin, which was stored at -80°C. Glycolysis Stress Test and 
Mitochondrial Stress Test kits were obtained from Seahorse Biosciences and used according to 
manufacturer instructions.  Briefly, the components were mixed and constituted the day of the 
experiment, and utilized only once (the kits have reagents that are divided for single-use 
purposes). Ethidium bromide and uridine were obtained from Sigma. 
Cell Culture: 
Cell lines used throughout this thesis include BRAF-mutated melanoma cells (WM115, WM165, 
WM88, WM1799, WM793, WM2664, WM983B, SKMEL5, SKMEL28, A375, and A2058), 
BRAF-WT melanoma cells (MEWO), triple-negative breast cancer cells (MDA-MB-231), and 
HER2+ breast cancer cells (HCC1954).  All melanoma cells were grown and cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) media containing 2 mM glutamine, 4.5 g/L 
glucose, 10% FBS and no sodium pyruvate (Gibco, catalog 11965-092), except where specified 
otherwise.  The HCC1954 and MDA-MB-231 cells were grown in RPMI-1640 media with 2 
mM glutamine, 2 g/L glucose, 10% FBS and no sodium pyruvate (Gibco, catalog 11875-093). 
Cells were split and seeded at ratios that allowed for splitting 1-2x per week. The cells were 
labeled lenti-virally with a fluorescent, nuclear tag (Histone 2B monomeric Red Fluorescent 
Protein, H2BmRFP from AddGene), flow sorted for H2BmRFP positivity (top 10-15% 
brightest), and kept as stocks annotated with “H2BmRFP”; if the cell line was labeled with the 
fluorescent ubiquitin-labeled cell cycle indicator FUCCI, then an additional annotation of 
“FUCCImAG-gem” was added as well. For proliferative experiments, the cells were plated the 
night before, then reagents/drugs were prepared in fresh media and added to the cells 
immediately before the start of the experiment the following day. For experiments involving 
nutrient deprivation (like glucose deprivation), cells were washed 1x with PBS then experimental 
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media was added onto the cells. For glucose deprivation, dialyzed FBS was added to DMEM 
medium to mitigate contribution of glucose from FBS. Dialyzed FBS+No glucose DMEM was 
titrated against the normal FBS+DMEM when preparing the drug dilutions for the experiments. 
Rho0 Cell Generation: 
Rho0 cell variants of BRAF-mutated cell lines WM164 and A2058 were generated using DMEM 
medium containing 4.5 g/L or 25 mM glucose, 2 mM glutamine, 1mM sodium pyruvate, 50 
µg/ml uridine and 50 ng/ml ethidium bromide; cells were passaged at least 10x in this medium 
before using in experiments. PCR was used to confirm loss/reduction of mtDNA as a ratio of 
mtDNA to nuclearDNA (data not shown). These cells are classically referred to as rho0 or ρ0. 
Measurement of Oxygen Consumption and Extracellular Acidification Rates: 
Cells were plated in 96-well plates (Seahorse Biosciences, Bilerica, MA) at a density of 25-
40,000 cells/well 24 hours before analysis on the Seahorse XFe 96 extracellular flux analyzer. 
Mitochondrial oxygen consumption was quantified using the Mito Stress Test kit, and glycolytic 
rate quantified using the Glycolysis Stress Test kit, each according to manufacturer’s 
instructions.  Briefly, assay medium was un-buffered DMEM containing either 10 mM Glucose, 
2 mM Glutamine, and 1 mM Sodium Pyruvate (Mito Stress Test) or none of the aforementioned 
(Glyco Stress Test). No FBS was used in assay medium.  
Proliferation Assays: 
The fluorescently labeled cells were counted under drug treatments using fluorescent 
microscopy. Cells were seeded into 96 well plates (1-5,000 cells per well) and drug treatments 
applied the following day, including DMSO or PBS control (all concentrations contained equal 
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percentage of DMSO or PBS solvent). Images were taken every 8-12 hours with sufficient image 
alignment (montaging) in order to capture about 25-100 cells per well/treatment (over the course 
of the experiment, cell counts typically exceed 1,000 in DMSO or low drug concentration wells). 
Direct measurements of cell counts were made using Cellavista software and Image J macros 
(please see Cell Counting Algorithms section in this Chapter). The images were filtered through 
these computer programs to track and label each cell, quantifying the number of cells in each 
time-stamped frame. Proliferation was plotted as log2 normalized growth, using the initial cell 
count from the first image frame for normalization.  
Cell Counting Algorithms: 
Image J macros are usually employed to directly count the cells. Raw microscopy images 
(usually in the highest, TIFF resolution format) are saved locally for the analysis. The macro 
identifies image files by 2 methods: 1) the file location or folder that is directed to “open,” and 2) 
the string characters in the file name such as “-R0” +R+ “-C0” +C. By understanding the naming 
convention of the Cellavista microscope, we designed macros that can pick and group the 
individual image files of each well, putting all the subfield images together (montaging). Below 
is an example of a macro used. After the images are pulled and concatenated into an image stack, 
the median background is subtracted, I threshold the images for optimal pixel visualization, then 
a series of commands are run using built-in Image J functions. The ending output is a count of 
the particles (or nuclei) present. 
Image J Macro Example: 
//SKMel5 treated on 2 dimensions with varying glucose and PLX4720 
//Have 7 time points taken, this plate is all SKMel5; washed 1x with PBS before drug addition 
//3 x 5 montage, so total 15 in number=15; There was a total of 10 plates run with this group 
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//this for loop pulls all wells in loop 
//for (R=row where to start; R< row to end at; same for column 
for (R=2; R<8; R++) { 
for (C=2; C<12; C++){ 
if (C < 10) 
WellNumber = "-R0"+R+"-C0"+C; 
else 
WellNumber = "-R0"+R+"-C"+C; 
time0 = "F:\\Keisha Hardeman\\hardemkn\\Melanoma\\March 2016\\20160325 SKMel5 
GlucPLX\\1\\"; 
time1 = "F:\\Keisha Hardeman\\hardemkn\\Melanoma\\March 2016\\20160325 SKMel5 
GlucPLX\\2\\"; 
time2 = "F:\\Keisha Hardeman\\hardemkn\\Melanoma\\March 2016\\20160325 SKMel5 
GlucPLX\\3\\"; 
time3 = "F:\\Keisha Hardeman\\hardemkn\\Melanoma\\March 2016\\20160325 SKMel5 
GlucPLX\\4\\"; 
time4 = "F:\\Keisha Hardeman\\hardemkn\\Melanoma\\March 2016\\20160325 SKMel5 
GlucPLX\\5\\"; 
time5 = "F:\\Keisha Hardeman\\hardemkn\\Melanoma\\March 2016\\20160325 SKMel5 
GlucPLX\\6\\"; 
time6 = "F:\\Keisha Hardeman\\hardemkn\\Melanoma\\March 2016\\20160325 SKMel5 
GlucPLX\\7\\"; 
run("Image Sequence...", "open=[time0] number=15 starting=1 increment=1 scale=100 
file=&WellNumber or=[] sort"); 
rename("stack"); 
run("Image Sequence...", "open=[time1] number=15 starting=1 increment=1 scale=100 
file=&WellNumber or=[] sort"); 
rename("time1"); 
run("Concatenate...", "  title=[Concatenated Stacks] image1=[stack] image2=[time1] image3=[-- 
None --]"); 
run("Image Sequence...", "open=[time2] number=15 starting=1 increment=1 scale=100 
file=&WellNumber or=[] sort"); 
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rename("time2"); 
run("Concatenate...", "  title=[Concatenated Stacks] image1=[Concatenated Stacks] 
image2=[time2] image3=[-- None --]"); 
run("Image Sequence...", "open=[time3] number=15 starting=1 increment=1 scale=100 
file=&WellNumber or=[] sort"); 
rename("time3"); 
run("Concatenate...", "  title=[Concatenated Stacks] image1=[Concatenated Stacks] 
image2=[time3] image3=[-- None --]"); 
run("Image Sequence...", "open=[time4] number=15 starting=1 increment=1 scale=100 
file=&WellNumber or=[] sort"); 
rename("time4"); 
run("Concatenate...", "  title=[Concatenated Stacks] image1=[Concatenated Stacks] 
image2=[time4] image3=[-- None --]"); 
run("Image Sequence...", "open=[time5] number=15 starting=1 increment=1 scale=100 
file=&WellNumber or=[] sort"); 
rename("time5"); 
run("Concatenate...", "  title=[Concatenated Stacks] image1=[Concatenated Stacks] 
image2=[time5] image3=[-- None --]"); 
run("Image Sequence...", "open=[time6] number=15 starting=1 increment=1 scale=100 
file=&WellNumber or=[] sort"); 
rename("time6"); 
run("Concatenate...", "  title=[Concatenated Stacks] image1=[Concatenated Stacks] 
image2=[time6] image3=[-- None --]"); 
run("Median...", "radius=2 stack"); 
run("Subtract Background...", "rolling=50 stack"); 
setThreshold(20, 255); 
run("Convert to Mask", " "); 
run("Watershed", "stack"); 
run("Analyze Particles...", "size=100-1500 circularity=0.60-1.00 show=Outlines exclude clear 
include summarize stack"); 
while (nImages>0) {  
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          selectImage(nImages);  
          close();  
      }  
} 
} 
The text is usually saved with basic text editors (ex: TextEdit on MAC processors) and the file 
name is annotated with the experiment date, and cell line name (and sometimes other pertinent 
information).  
Clonal Fractional Proliferation Assay: 
Clonal Fractional Proliferation (cFP) was done as previously described (Frick, Paudel, et al., 
2015). Briefly, sub-confluent cells are seeded at low density (~10–20 cells per well) in 96-well 
culture imaging plates. Plates are kept in humidified and CO2-controlled incubators for 
approximately one week with medium replacement every 3 days to allow single cells to expand 
into colonies of approximately 50 cells. Medium is then replaced with drug- or vehicle-
containing medium and cells are imaged every ~8–12 hours until the end of the experiment, with 
drug replacement every three days. Images are processed as follows: raw images are sequentially 
organized into spatially registered montages and temporally assembled into image stacks. Cell 
counts per colonies were obtained using the freely available software called ImageJ 
(https://imagej.nih.gov/ij/), with a custom-written macro as described previously (Frick, Paudel, 
et al., 2015). This macro differs from the population-counting macros described in the prior 
section of this Chapter. Growth curves of single cell-derived colonies were plotted as described 
above.  
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Single Cell Derived Subclones: 
SKMEL5 sublines were derived from single cells by serial dilution. Briefly, SKMEL5 cells were 
serially diluted and plated to less than 1 cell per well in 96-well imaging plates and imaged to 
identify wells containing a single cell. Cells were expanded in complete growth medium (in the 
absence of any inhibitors) and sequentially transferred to 48-, 24-, and 6-well plates until 
sufficient numbers of cells were available for cryopreservation of each subline. Sixteen such 
sublines were tested for their sensitivity to BRAF inhibitor (PLX4720) prior to cryopreservation 
(about 40+ sublines were produced from the entire assay, but most are not utilized in any 
experiments and have not been characterized).  
Time-Lapse Single Cell Tracking:  
For single-cell tracking, fluorescence images of nuclei were obtained as previously described 
(Quaranta, Tyson, et al., 2009). Briefly, images were acquired using a BD Pathway 855 in 
(spinning disk) confocal mode with a 20× (0.75NA) objective in a CO2- and temperature-
controlled environment every 20 min for 260 h from the time of first drug addition. Medium was 
replaced with freshly prepared drug every three days. Images from each well were organized into 
stacks of time series. Fluorescent nuclei were manually tracked across sequential images to 
obtain cell lifespans and resultant cell fates (death or division) as previously described (Tyson, 
Garbett, et al., 2012). “Birth time” denotes the time at which a mitotic event occurs, giving rise 
to two sister cells. “Lifetime” denotes the duration of single cell viability until they either died or 
underwent another mitosis. End of Experiment (EOE) represents the cells that were born in drug 
but did not exhibit any cell fate during the remaining observation time. A two-dimensional plot 
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of birth time (h) vs lifetime (h) shows the occurrence of differential cell fates in drug at the 
single-cell level.  
Principal Component Analysis (PCA) and Liner Regressions: 
Metabolic parameters were extracted for nine cell lines from two representative experiments, a 
glycolytic function experiment (Glyco Stress Test) and a mitochondria function experiment 
(Mito Stress Test) according to equations in supplemental table.  Bioenergetic Health Index was 
calculated as previously described by Chacko, Kramer, et al. 2014. Correlation between 
metabolic parameter and IC50 was calculated using Pearson correlation. Before principal 
component analysis (PCA), each extracted parameter was Z-score normalized to minimize 
variation due to the different parameter scales. The first principal component was calculated 
using all possible combinations of parameters and each combination was correlated with the 
measured IC50 for nine cell lines in panel.  All code for analysis is available in the public 
repository in GitHub: 
https://github.com/hardemkn/Hardeman_et_al_2016  
Statistical Analyses: 
Data are presented as either an average of 3+ separate experiments or a representative example; 
error bars are means + or – SD and p values were obtained using unpaired t-test (Gaussian 
distribution assumed, two-tailed) done in Prism 7. Statistics for PCA and IC50 calculation are 
described in preceding sections. Estimates of DIP rate are determined within an experiment using 
the sum of cells across all technical replicates at a given time point and obtaining the slope of a 
linear model of log2(cell number) ~ time for time points greater than the observed delay. 
Minimum delay time is estimated by visual inspection of log-growth curves for the time at which 
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they become approximately linear. All data analysis was performed in R (version 3.2.1) and all 
raw data and additional R analysis code is freely available at github.com/QuLab-
VU/DIP_rate_NatMeth2016. 
Publicly available data sets 
Drug-response data were obtained from the Genomics of Drug Sensitivity in Cancer (GDSC) 
project4,9 website at ftp://ftp.sanger.ac.uk/pub/project/cancerrxgene/releases/release-
5.0/gdsc_drug_sensitivity_raw_data_w5.zip and from the Cancer Cell Line Encyclopedia 
(CCLE)6 website at http://www.broadinstitute.org/ccle/ in the data file 
CCLE_NP24.2009_Drug_data_2015.02.24.csv (user login required). 
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CHAPTER III 
 
CELLULAR PROLIFERATION BIASES IN ONCOGENE-ADDICTED TUMORS: AN 
UNBIASED METRIC OF ANTIPROLIFERATIVE DRUG EFFECT IN VITRO 
 
Adapted From:  Harris LA, Frick PL, Garbett SP, Hardeman KN, et al. (2016). “An Unbiased 
Metric Of Antiproliferative Drug Effect In Vitro.” Nature Methods 13, 497-500. 
 
Abstract: 
 In vitro cell proliferation assays are widely used in pharmacology, molecular and cellular 
biology, and drug discovery. The gold standard metric is the number of viable cells remaining 72 
h after drug addition. This is a “static” drug effect metric, since it is a single-time-point 
measurement. We found that dose–response curves constructed using “static,” standard metrics 
of drug effect can result in erroneous and misleading values of drug-activity parameters, skewing 
data interpretation. This is because these metrics can suffer from time-dependent bias: i.e., the 
metric value varies with the time point chosen for experimental measurement. Using theoretical 
modeling and experimentation, we demonstrate these effects and possible inaccurate assessments 
of parameters such as drug potency and efficacy. To overcome this problem of bias, we propose 
using the slope of the proliferation response once it has linearized: a metric we call the drug-
induced proliferation (DIP) rate.  This DIP rate is essentially the slope of the line on a plot of cell 
population doublings (in log2 scale, on the y-axis) versus time (on the x-axis). My co-authors 
model mathematical, theoretical scenarios or treatments that could produce time-dependent 
biases in in vitro proliferation assays: (1) fast-proliferating cell line with a fast-acting drug, (2) 
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slow-proliferating cell line with a fast-acting drug, and (3) fast-proliferating cell line with a 
delayed-action drug.   
My contribution to this manuscript is primarily in the 2nd half where cell line data is 
utilized to demonstrate the validity of the theoretical models and metrics. Under the section 
“Experimental Demonstration of Time-Dependent Biases” within this chapter, data I generated 
on two breast cancer cell lines (HCC1954 and MDAMB231) is used to experimentally 
demonstrate the scenarios of fast-proliferating cells treated with either fast-acting drugs (the 
metabolic inhibitors rotenone and phenformin) or slow-acting drugs (the tyrosine kinase 
inhibitors lapatinib and erlotinib). We generate dose–response curves from those data using the 
standard static effect metric and our novel DIP rate for various drug exposure times. Consistent 
with our theoretical results, the shape of the static-based dose–response curve strongly depended 
on the time point at which cell counts were taken: an illustration of time-dependent bias. These 
data make up the majority of Figure 3.5 of this chapter. Additionally, proliferative response data 
I collected using BRAF-mutated melanoma cell lines is included in the section title “Biases 
Found For Melanoma Cell Lines In Public Data Sets.” Theoretically and in our hands we show 
that time-dependent biases can shape the metrics we obtained from proliferative assays; 
naturally, we wondered if these biases exist in public datasets. We extracted IC50 values from 
four BRAF-mutated melanoma cell lines (SKMEL5, A2058, A375, and WM115) that were 
shared in common within two large public data sets: the Cancer Cell Line Encyclopedia (CCLE) 
and the Genomics of Drug Sensitivity in Cancer (GDSC). Comparison-wise, our IC50 values 
corresponded closely to the value from at least one of the public data sets. Furthermore, in three 
cases the static- and DIP-rate-based IC50 values corresponded within an order of magnitude, 
however in one case (A375), they differed by nearly two orders of magnitude. This discrepancy 
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can be traced to a period of complex, nonlinear dynamics (brief regression followed by rebound) 
observed for this cell line between 24 h and 72 h post drug addition.  
Introduction: 
Evaluating antiproliferative drug activity on cells in vitro is a widespread practice in 
basic biomedical research (Zuber, McJunkin, et al., 2011; Berns, Hijmans, et al., 2004; Bonnans, 
and Werb, 2014) and drug discovery (Garnett, Edelman, et al., 2012; Wang, McLeod, et al., 
2011; Barretina, Caponigra, et al., 2012). Typically, quantitative assessment relies on 
constructing dose–response curves (Stephenson, 1956). Briefly, a drug is added to a cell 
population over a range of concentrations, and the effect on the population is quantified with a 
metric of choice (Fallahi-Sichani, Monarnejad, et al., 2013). The de facto standard metric is the 
number of viable cells 72 h after drug addition (Garnett, Edelman, et al., 2012; Barretina, 
Caponigra, et al., 2012; Fallahi-Sichani, Monarnejad, et al., 2013; Yang, Soares, et al., 2013). 
Since this is a single-time-point measurement, we refer to it as a 'static' drug effect metric. The 
data is then fit to the Hill equation (Goutelle, Maurin, et al., 2008), a four-parameter log-logistic 
function, to produce a sigmoidal dose–response curve that summarizes the relationship between 
drug effect and concentration. Parameters extracted from these curves include the maximum 
effect (Emax), half-maximal effective concentration (EC50), half-maximal inhibitory 
concentration (IC50), area under the curve (AUC), and activity area (AA) (Garnett, Edelman, et 
al., 2012; Barretina, Caponigra, et al., 2012; Fallahi-Sichani, Monarnejad, et al., 2013; Yang, 
Soares, et al., 2013). These are useful for quantitatively comparing various aspects of drug 
activity across drugs and cell lines (Figure 3.1). 
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Figure 3.1: Different Formulations of Dose Curve Parameters. Potency parameters EC50 and 
IC50 are shown, as are area under the curve (AUC) and activity area (AA; the inverse of AUC), 
parameters that attempt to capture both potency and efficacy in a single quantity. (a) The 
“scaled” form given in equation (S2); (b) The “direct effect” form obtained by rearranging 
equation (S2) to solve for Edrug; (c) The “response ratio” form obtained by dividing the direct-
effect form by E0. Note that we consider here a case where Emax < 0, which is possible when 
using a dynamic drug effect metric such as DIP rate. This results in IC50 < EC50 (see equation 
S5). In cases like this, the IC50 is sometimes referred to as the GI50 (half-maximal growth 
inhibitory concentration). (Figure Contribution: Leonard Harris and Darren Tyson) 
 
We contend that dose–response curves constructed using standard metrics of drug effect 
can result in erroneous and misleading values of drug-activity parameters, skewing data 
interpretation. This is because these metrics suffer from time-dependent bias: i.e., the metric 
value varies with the time point chosen for experimental measurement. We identify two specific 
sources of time-dependent bias: (i) exponential growth and (ii) delays in drug effect stabilization. 
The former can lead to erroneous conclusions (e.g., that a drug is increasing in efficacy over 
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time), while the latter requires shifting the window of evaluation to only include data points after 
stabilization has been achieved (Figure 3.2). 
To overcome this problem of bias, we propose as an alternative drug effect metric the 
drug-induced proliferation (DIP) rate (Tyson, Garbett, et al. 2012; Frick, Paudel, et al. 2015), 
defined as the steady-state rate of proliferation of a cell population in the presence of a given 
concentration of drug. Using related approaches, we previously quantified clonal fitness (Frick, 
Paudel, et al. 2015) and heterogeneous single-cell fates (Tyson, Garbett, et al., 2012) within cell 
populations responding to perturbations. Here, we show that DIP rate is an ideal metric of 
antiproliferative drug effect because it naturally avoids the bias afflicting traditional metrics, it is 
easily quantified as the slope of the line on a plot of the doubling of cell populations versus time 
(Figure 3.2), and it is interpretable biologically as the rate of regression or expansion of a cell 
population. 
 
Figure 3.2: Action of Drugs On Proliferation. Hypothetical growth curves (in log scale) for a 
cell line untreated and treated with two different drugs: a fast-acting drug where the full effect is 
achieved immediately, and a slow-acting drug that causes a temporal delay in the stabilization of 
the drug effect. Also shown is drug-induced proliferation (DIP) rate, defined as the slope of the 
line after the drug effect has stabilized (in this case, immediately for the fast-acting drug and 
≥48h for the slow-acting drug). Note that the DIP rate is shown as equivalent for both the fast- 
and slow-acting drugs for illustration purposes only. (Figure Contribution: Leonard Harris and 
Darren Tyson) 
	 34	
Results: 
Theoretical Illustration of Biases in Drug Dose-Response Curves 
To theoretically illustrate the consequences of time-dependent bias in standard drug 
effect metrics, we constructed a simple mathematical model of cell proliferation that exhibits the 
salient features of cultured cell dynamics in response to drug (Figure 3.3). The model assumes 
that cells experience two fates, division and death, and that the drug modulates the difference 
between the rates of these two processes, i.e., the net rate of proliferation. Drug action may occur 
immediately or gradually over time, depending on the chosen parameter values. In all cases, a 
stable DIP rate is eventually achieved and, when calculated over a range of drug concentrations, 
a sigmoidal dose–response relationship emerges (Figure 3.3). 
 
Figure 3.3: Figure legend on next page. 
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Figure 3.3: Mathematical Model of Cell Proliferation.  (a) The model assumes two states, a 
drug-naïve state and a drugged state, each with its own characteristic rate of proliferation (DIP0 
and DIPmax, respectively), which is the difference between the rates of cell division and death. 
The rate of transition from the drug-naïve state to the drugged state depends on the concentration 
of drug, while the reverse transition does not. Hence, as the concentration of drug increases, the 
dynamic equilibrium between states shifts increasingly in favor of the drugged state. (b) Since 
the action of an antiproliferative drug is to reduce, and perhaps reverse, the rate of proliferation 
of a cell population, we assume that the proliferation rate of the drug-naïve state is positive and 
greater than that of the drugged state (which may be positive or negative). In Figure 3.4 of this 
chapter, we assume that in each case the drug is cytotoxic at saturating drug concentrations (i.e., 
causes regression of the cell population). Hence, the DIP rate of the drugged state (DIPmax) is 
assumed to be negative. (c) An example dose–response curve predicted by the two-state model 
under the partial equilibrium assumption (PEA). The curve was generated from equation (S27) 
with EC50 = 1e–8 M, DIP0 = 0.06*ln(2) h-1, and DIPmax = –0.03*ln(2) h-1. (d) An example dose–
response curve predicted by the two-state model in conditions where the PEA does not hold. The 
curve was generated by numerical integration of equations (S12) and (S13) with kon = 1e5 M-1 h-
1, koff = 1e–3 h-1, kdiv– kdeath = 0.06*ln(2) h-1, and kdiv* – kdeath* = –0.03*ln(2) h-1. Note that these 
are consistent with the values used in part (c); see equations (S22), (S23), and (S26). Arrows 
highlight largest differences between calculated values (circles) and the Hill equation fit (black 
line). (Figure Contribution: Leonard Harris and Darren Tyson) 
 
We model three scenarios: treatment of a fast-proliferating cell line with a fast-acting 
drug (Figure 3.4, part a), treatment of a slow-proliferating cell line with a fast-acting drug 
(Figure 3.4, part b), and treatment of a fast-proliferating cell line with a delayed-action drug 
(Figure 3.4, part c). In each case, we generate simulated growth curves in the presence of 
increasing drug concentrations (Figure 3.4, columns 1 and 2) and from these produce static dose–
response curves by taking cell counts at single time points between 12 h and 120 h (Figure 3.4, 
column 3). As expected, in each scenario the shape of the dose–response curve varies depending 
on the time of measurement. Consequently, parameter values (EC50 and AA) extracted from 
these curves also vary (Figure 3.4, columns 4 and 5). Similar results are obtained for an 
alternative drug effect metric proposed by the U.S. National Cancer Institute's Developmental 
Therapeutics Program (Shoemaker, 2006). In contrast, as DIP rate is the slope of a line, it is 
independent of measurement time. Using it as the drug effect metric gives a single dose–
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response curve (Figure 3.4, columns 3 and 6) and single values of the extracted drug-activity 
parameters (Figure 3.4, columns 4 and 5).  
 
 
 
Figure 3.4: Theoretical Illustration of Time-dependent Bias. Computational simulations of 
the effects of drugs on: (a) a fast-growing cell line treated with a fast-acting drug; (b) a slow-
growing cell line treated with a fast-acting drug; (c) a fast-growing cell line treated with a slow-
acting drug. In all cases, in silico growth curves, plotted in linear (column 1) and log2 (column 2) 
scale, are used to generate static- (column 3) and DIP rate-based (columns 3 and 6) dose–
response curves, from which values of EC50 (column 4) and activity area (AA; column 5) are 
extracted. For DIP rate-based values of EC50 and AA, the black triangle denotes the first time 
point used to calculate the DIP rate (i.e., after the drug effect has stabilized; see Online 
Methods); the black dashed line signifies that the value remains constant for all subsequent time 
points. Note that the “response ratio” (column 3) and “direct effect” (column 6) versions of the 
DIP rate-based dose–response curves (Figure 3.1) convey complementary information about the 
activity of a drug on a cell line. (Figure Contribution: Leonard Harris and Darren Tyson) 
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Experimental Demonstration of Time-Dependent Biases 
As a first confirmation of our theoretical findings, we subjected triple-negative breast 
cancer cells (MDA-MB-231) to the metabolic inhibitors rotenone (Figure 3.5, part a) and 
phenformin (Figure 3.5, part b). Using fluorescence microscopy time-lapse imaging (Tyson, 
Garbett, et al., 2012; Frick, Paudel, et al., 2015; Quaranta, Tyson, et al., 2009), we quantified 
changes in cell number over time for a range of drug concentrations. For both drugs, we 
observed a rapid stabilization of the drug effect (<24 h delay) and stable exponential proliferation 
thereafter, reminiscent of the growth dynamics of the theoretical cell lines treated with fast-
acting drugs. We generated dose–response curves from these data using the standard static effect 
metric and DIP rate for various drug exposure times. Consistent with our theoretical results, the 
shape of the static-based dose–response curve strongly depended on the time point at which cell 
counts were taken, an illustration of time-dependent bias. The DIP rate, on the other hand, was 
free of time-dependent bias and produced a single dose–response curve in both cases.  
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Figure 3.5: Figure legend on next page. 
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Figure 3.5: Experimental Confirmation of Time-dependent Bias. Population growth curves 
(log2 scaled) and derived dose–response curves (static- and/or DIP rate-based) for (a) MDA-
MB-231 triple-negative breast cancer cells treated with rotenone; (b) MDA-MB-231 cells treated 
with phenformin; (c) three single-cell-derived drug-sensitive (DS) clones of the EGFR mutant-
expressing lung cancer cell line PC9 treated with erlotinib; (d) HCC1954 HER2-positive breast 
cancer cells treated with erlotinib and lapatinib. Data for (a) and (b) are from single experiments 
with technical duplicates; data in (c) are from individual wells for two experiments containing 
technical duplicates (growth curves) and from a single experiment with technical duplicates 
(dose–response curves); data in (d) are sums of technical duplicates from a single experiment 
(growth curves) and mean values (circles) with 95% confidence intervals (gray shading) on the 
log-logistic model fit (dose–response curves; n=4, 6 for erlotinib and lapatinib, respectively).  
 
These DIP-rate-based dose–response curves produce interesting insights (Figure 3.5, 
parts a and b). For example, they indicate that while rotenone is much more potent than 
phenformin (EC50 ≅ 8.5 nM versus 25 µM), phenformin is more effective (Emax/E0 ≅ −0.1 
versus 0.1). The static dose–response curves can discriminate the ordering of potencies (rotenone 
>> phenformin) but not the ordering of efficacies: i.e., the static drug effect metric obscures the 
crucial fact that at saturating concentrations phenformin is cytotoxic (cell populations regress) 
while rotenone is partially cytostatic (cell populations continue to expand slowly). This 
information is critical to studies assessing drug mechanism of action. This example illustrates the 
perils of biased drug effect metrics and the ability of DIP rate to produce reliable dose–response 
curves from which accurate quantitative and qualitative assessments of antiproliferative drug 
activity can be made. 
To illustrate the confounding effects that a delay in the stabilization of the drug effect can 
have, we examined single-cell-derived clones of the lung cancer cell line PC9, which is known to 
be hypersensitive to erlotinib (Gong, Somwar, et al., 2007), an epidermal growth factor receptor 
(EGFR) kinase inhibitor. Consistent with our previous report (Tyson, Garbett, et al., 2012), three 
drug-sensitive PC9-derived clones (DS3, DS4, and DS5) each responded to 3 µM erlotinib with 
nonlinear growth dynamics over the first 48–72 h, followed by stable exponential proliferation 
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thereafter (Figure 3.5, part c). These dynamics are reminiscent of those for the theoretical fast-
proliferating cell line with a delayed-action drug (Figure 3.4, part c). Because of the delay in 
drug action, all three clones had nearly identical population sizes 72 h after drug addition for all 
concentrations considered. The static 72-h metric thus produces essentially identical dose–
response curves for all clones (data not shown). In contrast, dose–response curves based on DIP 
rate make a clear distinction between the clones in terms of their long-term response to drug: i.e., 
erlotinib is cytotoxic (negative DIP rate) for two of the clones but partially cytostatic (positive 
DIP rate) for the other (Figure 3.5, part c).  
We then investigated the effects of erlotinib and lapatinib (a dual EGFR/human EGFR 2 
(HER2) kinase inhibitor) on HER2-positive breast cancer cells (HCC1954; delay ~48 h; Figure 
3.5, part d). In each case, DIP-rate-based dose–response curves produced EC50 values more than 
five-fold larger than their static counterparts; i.e., by the static drug effect metric the drugs 
appeared significantly more potent than they actually were. Taken together with the PC9 results 
(Figure 3.5, part c), these data illustrate the importance of accounting for delays in drug action 
when assessing antiproliferative drug activity, and they further emphasize the ability of the DIP 
rate metric to produce accurate drug-activity parameters and qualitative conclusions about drug-
response dynamics. 
 
Biases Found For Melanoma Cell Lines In Public Data Sets 
Within the last several years, a number of studies have been published reporting drug 
responses for hundreds of cell lines derived from various cancer types (Garnett, Edelman, et al., 
2012; Barretina, Caponigra, et al., 2012; Yang, Soares, et al., 2013; Seashore-Ludlow, Rees, et 
al., 2015; Rees, Seashore-Ludlow, et al. 2016) and organ sites (Fallahi-Sichani, Honarnejad, et 
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al., 2013; McDermott, Sharma, et al., 2008; Heiser, Wang, et al., 2009). Raw data are available 
for the responses of over 1,000 cancer cell lines to a panel of 24 drugs in the Cancer Cell Line 
Encyclopedia (CCLE) (Barretina, Caponigra, et al., 2012) and for the responses of over 1,200 
cell lines to 140 drugs in the Genomics of Drug Sensitivity in Cancer (GDSC) project (Yang, 
Soares, et al., 2013). These data are largely based on 72-h cell counts, a metric that we have 
shown contains time-dependent bias. 
To investigate bias in these data sets, we treated four BRAFV600E- or BRAFV600D-
expressing melanoma cell lines with various concentrations of the BRAF-targeted agent 
PLX4720, an analog of vemurafenib. We produced experimental growth curves (Figure 3.6, part 
a) and static- and DIP-rate-based dose–response curves (Figure 3.6, part b), and we extracted 
IC50 values for each cell line and compared these to IC50 values obtained from the CCLE and 
GDSC data sets (Figure 3.6, part c). In all cases, our IC50 values corresponded closely to the 
value from at least one of the public data sets. While in three cases the static- and DIP-rate-based 
IC50 values corresponded within an order of magnitude, in one case (A375), they differed by 
nearly two orders of magnitude. This discrepancy can be traced to a period of complex, nonlinear 
dynamics (brief regression followed by rebound) observed for this cell line between 24 h and 72 
h post drug addition (Figure 3.6, part a). This result is particularly intriguing because it shows 
that, based on DIP rate, this cell line is not much different than the other three cell lines in terms 
of drug sensitivity. Using the biased static drug effect metric, however, one would be led to the 
incorrect conclusion that it is significantly more sensitive. It is likely that cases like this abound 
within these and other similar data sets (Seashore-Ludlow, Rees, et al. 2015; Rees, Seashore-
Ludlow, et al. 2016), and this likelihood illustrates the critical need for new antiproliferative drug 
effect metrics.  
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Figure 3.6: Bias In Potency Metrics Found In Public Datasets. (a) Population growth curves 
(log2 scaled) for four select BRAF-mutant melanoma cell lines treated with various 
concentrations of the BRAF inhibitor PLX4720; (b) dose–response curves based on the static 
effect metric (colored lines) and DIP rate (black line); (c) static- (circles) and DIP rate-based 
(triangle+line) estimates of IC50 for each measurement time point. IC50 values obtained from 
public data sets (CCLE: Cancer Cell Line Encyclopedia; GDSC: Genomics of Drug Sensitivity 
in Cancer), based on the static 72h drug effect metric, are included for comparison. The triangle 
denotes the first time point used in calculating the DIP rate and the black line signifies that the 
value remains constant for all subsequent time points. Data shown are from a single experiment 
with technical duplicates. Experiment has been repeated at least twice with similar results. 
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Discussion: 
Current protocols for cell proliferation assays are based on informal 'rules of thumb', for 
example, counting cells after 72 h of treatment to ameliorate the impact of complex dynamics 
and delays in drug response. However, these de facto standards have no theoretical basis and, as 
demonstrated here, they suffer from time-dependent bias that leads to erroneous conclusions. In 
light of the widespread applications of cell proliferation assays in oncology, pharmacology, and 
basic biomedical science (Sporn, & Harris, 1981) (for example, to assess activity of cytokines, 
cell surface receptors, altered signaling pathways, gene overexpression and silencing, or cell 
metabolic adaptation to varied microenvironmental conditions), it is imperative that the quality 
of the metric for antiproliferative assays be improved. Toward this end, we have proposed DIP 
rate as a viable, unbiased alternative antiproliferative drug effect metric. DIP rate overcomes 
time-dependent bias by log-scaling cell count measurements to account for exponential 
proliferation and by shifting the time window of evaluation to accommodate lag in the action of a 
drug, changes that do not substantially alter experimental design (Supplementary Note and 
Supplementary Figs. 6, 7, 8, 9). Moreover, DIP rate is an intuitive, biologically interpretable 
metric with a sound basis in theoretical population dynamics, and it faithfully captures, within a 
single value, the long-term effect of a drug on a cell population.  
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CHAPTER IV 
 
DEPENDENCE ON GLYCOLYSIS SENSITIZES BRAF-MUTATED MELANOMA FOR 
INCREASED RESPONSE TO BRAF INHIBITION  
 
Adapted From:  Hardeman KN, Peng C, Paudel BB, Meyer CT, et al. (2017). “Dependence On 
Glycolysis Sensitizes BRAF-mutated Melanoma For Increased Response To BRAF Inhibition.” 
Scientific Reports 7; 42604. 
 
Abstract: 
Dysregulated metabolism can broadly affect therapy resistance by influencing 
compensatory signaling and expanding proliferation. Given many BRAF-mutated melanoma 
patients experience disease progression with targeted BRAF inhibitors, we hypothesized 
therapeutic response is related to tumor metabolic phenotype, and that altering tumor metabolism 
could change therapeutic outcome. We demonstrated the proliferative kinetics of BRAF-mutated 
melanoma cells treated with the BRAF inhibitor PLX4720 fall along a spectrum of sensitivity, 
providing a model system to study the interplay of metabolism and drug sensitivity. We 
discovered an inverse relationship between glucose availability and sensitivity to BRAF 
inhibition through characterization of metabolic phenotypes using nearly a dozen metabolic 
parameters in Principle Component Analysis. Subsequently, we generated rho0 variants that 
lacked functional mitochondrial respiration and increased glycolytic metabolism. The rho0 cell 
lines exhibited increased sensitivity to PLX4720 compared to the respiration-competent parental 
lines. Finally, we utilized the FDA-approved antiretroviral drug zalcitabine to suppress 
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mitochondrial respiration and to force glycolysis in our cell line panel, resulting in increased 
PLX4720 sensitivity via shifts in EC50 and Hill slope metrics.  Our data suggest that forcing 
tumor glycolysis in melanoma using zalcitabine or other similar approaches may be an adjunct to 
increase the efficacy of targeted BRAF therapy. 
Introduction: 
Melanoma is the most malignant form of skin cancer, and roughly 50% of clinical 
isolates have a mutation in the BRAF kinase of the mitogen-activated protein kinase (MAPK) 
pathway (Davies, Bignell, et al., 2002; Ribas and Flaherty, 2011). Ninety percent of those BRAF 
mutations are missense mutations that change the valine at position 600 to glutamic acid 
(V600E) or aspartic acid (V600D) (Ascierto, Kirkwood, et al., 2012). The mutation confers 
constitutive activation of the BRAF kinase and drives oncogenic signaling through MEK 
phosphorylation. Targeted therapies against the mutant BRAF have prolonged progression-free 
survival and overall survival in Phase III clinical trials (Chapman, Hauschild, et al., 2011). 
Unfortunately, most patients will exhibit some degree of disease progression while treated with a 
BRAF inhibitor, with nearly 50% of patients progressing after only 6 to 7 months of initial 
treatment (Chan, Haydu, et al., 2014).  There have been a variety of mechanisms that underlie 
initial and acquired drug resistance described in the literature. Generally, mechanisms of 
resistance to anti-BRAF therapies are put into MEK-dependent and MEK-independent 
categories. MEK-dependent mechanisms include mutations in NRAS, MEK1 and MEK2 
(Nazarian, Shi, et al., 2010), loss of RAS regulation by NF1 (Hodis, Watson, et al., 2012; 
Whittaker, Theurillat et al., 2013), COT overexpression driving MEK signaling (Johannessen, 
Boehm, et al., 2010), and genetic alterations in BRAF itself, such as truncation or amplification 
(Poulikakos, Persaud, et al., 2011). MEK-independent mechanisms of resistance include receptor 
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tyrosine kinase protein and ligand overexpression, such as cMET, IGF1R, and PDGFRb 
(Nazarian, Shi, et al., 2010), and signaling through PI3K (Villanueva, Vultur and Herlyn, 2011). 
Unfortunately, more than 40% of the resistance found in patients who progressed on targeted 
therapy cannot be attributed to any of these mechanisms Rizos, Menzies, et al., 2017). One of the 
features common to all of the known pathways that contribute to resistance is that they exert 
direct or indirect control of multiple cellular metabolic pathways—contributing to the single 
“hallmark” of metabolic reprogramming. In the last several years, there has been an increasingly 
intense focus on tumor metabolism as an exploitable therapeutic avenue (Vander Heiden, 
Cantley, et al., 2009; DeBerardinis, Lum, et al., 2008; DeBerardinis, and Chandel, 2016; 
Hanahan and Weinberg, 2011), with the success of asparaginase in the treatment of acute 
lymphoblastic leukemia (ALL) being just one example that has achieved widespread clinical use 
(Clavell, Gelber, et al., 1986; Silverman, Gelber, et al., 2001), and with many other metabolism-
based therapies under active development (Wang, Karamanlidis, and Tian, 2016; Zhao, Butler, 
and Tan, 2013). 
Dysregulated metabolism in cancer has been shown to affect treatment outcome via 
multiple pathways, including the activation of compensatory receptor tyrosine kinase signaling to 
bypass molecular targeted therapies, the repression of pro-apoptotic signaling, and limitation of 
drugs’ access to molecular targets through active and passive mechanisms (Zhao, Butler, and 
Tan, 2013). Komurov et al showed chronic lapatinib treatment of HER2+ breast cancer cell lines 
produced cells with an advanced nutrient starvation phenotype Komurov, Tseng, et al., 2012).  
Furthermore, the cells were sensitive to the antihelminthic pyrvinium pamoate, which targets 
mitochondrial function under various conditions (Tomitsuka, Kita, and Esumi, 2012), 
particularly glucose deprivation (Esumi, Kurashima, and Hanaoka, 2004).  Recently, it has been 
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shown in BRAF-mutated melanoma that chronic treatment with BRAF inhibitor induces 
glutamine dependence that correlates with drug resistance (Baenke, Chaneton, et al., 2015; 
Hernandez-Davies, Tran, et al., 2015). We were interested in the prospect that the molecular 
metabolic landscape of any individual tumor might have a direct relationship to its sensitivity to 
targeted therapies.  
The same metabolic pathways that have been targets for investigation in other 
malignancies have also been explored in BRAF-mutated melanoma, but a consensus of the major 
metabolic program exhibited by BRAF-mutated melanomas, or even whether a single dominant 
metabolic program exists, is lacking. BRAF-mutated melanomas have conversely been 
characterized as exhibiting primarily aerobic glycolysis (Parmenter, Kleinschmidt, et al., 2014) 
or oxidative phosphorylation (Vazquez, Lim, et al., 2013; Haq, Shoag, et al., 2013). Moreover, 
the relationship between metabolic program and therapeutic response in BRAF-mutated 
melanoma is poorly understood, so we set out to probe the phenotypic relationship of 
metabolism and responses to the BRAF inhibitor vemurafenib. 
In the present study, we used a panel of human BRAF-mutated melanoma cell lines to 
demonstrate in vitro variability in response to PLX4720, a BRAF inhibitor and analogue of 
vemurafenib.  Utilizing our previously described method for measuring proliferative rate under 
various treatment conditions (Harris, Frick, et al., 2016), we calculated a metric describing the 
dependence of proliferation on drug concentration to place the cell lines on a continuum of 
sensitivity to PLX4720. We then examined baseline glycolytic and oxidative metabolism and 
found a relationship between reliance on glycolysis and sensitivity to inhibition by PLX4720.  
Building upon this observation, we show that forcing exclusive reliance on glycolysis via 
mitochondrial DNA depletion using either ethidium bromide or zalcitabine (a first generation 
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antiretroviral used to treat HIV) significantly attenuates intrinsic resistance to PLX4720 in our 
cell line panel. 
Results:  
PLX4720 Response Spectrum and Global Metabolism 
To confirm the variability in response to mutant BRAF inhibition observed in patients 
could be modeled in vitro, we measured the cell lines’ proliferative responses to BRAF 
inhibition. The proliferative kinetics of the cell lines were quantified in the presence of 
PLX4720. Based on the PLX4720-treated DIP rates, BRAF-mutated melanoma cell lines fall 
along a response spectrum or continuum (Figure 4.1), from highly sensitive (e.g., WM164) to 
largely insensitive (A2058). The IC50 metric is calculated from a log-logistic curve fit to the 
estimated rate of proliferation obtained at each drug concentration, known as the drug-induced 
proliferation (DIP) rate (Harris, Frick, et al., 2016).  
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Figure 4.1: Heterogeneous Responses to BRAF Inhibition. Proliferative spectrum of IC50’s 
for PLX4720 based on DIP rate. The dose-response curves are generated using a 2-fold dilution 
of PLX4720 from 32 µM down to zero (DMSO). The proliferative rates are calculated using the 
slope of the log2-normalized population curve after 48 hours. Mean responses are shown as solid 
lines, 95% confidence intervals as shaded regions. All results are based on 3+ biological 
replicates.  
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We next wanted to confirm that the measured variability in response to PLX4720 
treatment was not due to phenotypic selection of drug-resistant subclones during the short 4-5 
day timeframe of our experiments. We leveraged a fluorescent ubiquitin-dependent cell cycle 
indicator (FUCCI; mAG-gem1-110) to detect cells that have committed to cell division (i.e. 
passed the G1/S transition). We reasoned that if intrinsically resistant clones exist within the 
population, they would be enriched in cells that continue to proliferate in the presence of BRAF 
inhibition and would remain resistant after isolation. To test this, we treated the BRAF-mutated 
melanoma lines with PLX4720 or DMSO for 72 hours followed by flow sorting for the actively 
dividing FUCCI+ cells from both groups, then re-plated them in the absence of drug for 24 h and 
treated a second time with PLX4720. The proliferative responses of the two groups were 
essentially the same, indicating that PLX4720 does not appear to select for resistant populations 
in the short term (Figure 4.2). Stated differently, cells that actively divide in the presence of 
PLX4720 have similar proliferation kinetics when re-challenged with the drug. 
 
 
Figure 4.2 Figure legend on next page. 
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Figure 4.2: FUCCI-sorting Experiment: Cells Retain No Memory. Schematic outline of the 
flow of the experimental design: A375 cells were pre-treated for 72 hours with either DMSO or 
PLX4720, then flow sorted for positive fluorescence-ubiquitin-linked cell cycle indicator 
(FUCCI). Those cells were seed in 96 well plates overnight, then retreated with PLX4720.  The 
proliferation was log-2 normalized and plotted as population doubling (y-axis) over time (x-axis, 
in hours). Data shown are from a single experiment with technical duplicates; experiment has 
been repeated with similar results.  
 
To determine the metabolic profiles exhibited by our panel of BRAF-mutated 
melanomas, we quantified lactate-producing glycolysis and mitochondrial oxidative metabolism 
using the Seahorse extracellular flux analyzer platform.  Using a panel of 10 BRAF-mutated 
melanoma cell lines, we found most lines can variably utilize glucose and consume oxygen as 
part of mitochondrial respiration (Figure 4.3). Notably, most cells have minor glycolytic reserve 
after the addition of oligomycin (Figure 4.3, lower), indicating most of the melanoma cell lines 
are functioning at or near their glycolytic capacity. The basal respiration and oxygen 
consumption also varied across cell lines. Additionally, the subsequent decreases in oxygen 
consumption rate (OCR) after the addition of oligomycin (Figure 4.3, upper) suggest varying 
dependencies on ATP-linked respiration (or ATP turnover supported by oxidative 
phosphorylation) across the cell lines.  In totality, these data suggest broad, intrinsic metabolic 
heterogeneity across the cell line panel. 
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Figure 4.3: Global Oxidative Phosphorylation and Glycolysis. Upper: Oxygen consumption 
profiles for the cell lines with sequential additions of oligomycin (1 µM), FCCP (1 µM) and 
Rotenone/Antimycin A (0.5 µM). Lower: Extracellular pH profiles for the cell lines with 
sequential additions of glucose (10 mM), oligomycin (1 µM), and 2-deoxyglucose (0.5 µM). 
Data shown are from a single experiment with minimum 5 technical replicates; experiment has 
been repeated at least twice with similar results. Error bars are standard deviation.  
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Given the observed heterogeneity in PLX4720 responses without an obvious biological 
mutational trend (Figures 4.1 and Table 1) and the variable metabolic strategies employed by our 
panel of BRAF-mutated melanomas, we sought to examine more closely whether a direct 
relationship exists between metabolism and drug response.  
 
Table 1. Relevant Mutation Biology and Calculated IC50. Cell line mutation information 
from WISTAR Institute website, COSMIC website, and Birgit Schittek, et al., Int J. of Cancer; 
82, 583-585 (1999). HOMOZ=homozygous; MU=mutated; WT=wild type; HEM 
DEL=hemizygous deletion 
 
Glucose Is A Key Nutrient Influencing Response 
To quantify the relationship between the metabolic program of BRAF-mutated melanoma 
cell lines and PLX4720 response, eleven metabolic parameters were calculated from 
measurements of mitochondrial oxygen consumption and glycolytic function curves for nine cell 
lines (parameters described in Figure 4.4 schema).  
	 55	
 
Figure 4.4: Schema For Principal Component Analysis. Schematic diagram describing the 
components and metrics from Seahorse assays used in the PCA; Bioenergetic Health Index 
(BHI) calculation is described in methods. 
 
Each metabolic parameter was independently tested for correlation with the measured IC50 for 
PLX4720 for each cell line (Figure 4.5).  We found a significant inverse correlation (r = -0.495) 
between glycolysis and the measured IC50 values, suggesting increased glycolysis in BRAF-
mutant cell lines is indicative of greater sensitivity to BRAF inhibition (and thus a lower IC50).   
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Figure 4.5: Independent Correlation Analysis. Metabolic parameters individually tested for 
correlation (Pearson) to PLX4720 IC50 of the cells. Parameters include: Non-mitochondrial 
respiration; Basal respiration; ATP production; Bioenergetic health index; Proton leak; Max 
respiration; Spare capacity; Glycolysis; Glycolytic capacity; Glycolytic reserve; and Non-
glycolytic acidification. 
 
Next we determined how different combinations of the metabolic parameters correlated 
with drug sensitivity using Principle Component Analysis (PCA). This analysis comparing all 
possible combinations of parameters identified a linear combination of glycolysis and glycolytic 
reserve as strongly correlating to the cell line's IC50 values, with the combination of these two 
metabolic parameters accounting for more than two-thirds (69.7%) of the variance in the 
parameter ensemble across the cell line panel (Figure 4.6).  Based on these results, we predicted 
increasing the rate of glycolysis while depleting glycolytic reserve would decrease the IC50 
value for a BRAF-mutated melanoma to PLX4720 treatment. 
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Figure 4.6: PCA Analysis. The first principle component of a linear combination of glycolysis 
and glycolytic reserve parameters (in cell lines) correlates with IC50. Corr=correlation. 
 
We titrated across serial dilutions of PLX4720 and glucose concentrations to test whether 
glucose availability and PLX4720 response were functionally related. We first quantified drug-
induced proliferative (DIP) rates across the spectrum of glucose/PLX4720 conditions in 6 
melanoma cell lines. We found that the DIP rate responses are largely linear and 
glucose/PLX4720 concentration dependent, as shown in Figure 4.7. Glucose-replete conditions 
exhibited the “best” or highest DIP rates for each cell line (indicating more rapid cell 
proliferation), and the glucose-deprived conditions the poorest or lowest DIP rates, as might have 
been expected. The key finding was each cell line appears to have the capacity to revert 
phenotypically to a more PLX4720-sensitive phenotype (i.e. lower DIP rate) by simply lowering 
the glucose in the medium, and every cell line exhibited sensitivity to glucose limitation to 
approximately the same degree. Using proliferation as a phenotypic output, every cells’ 
phenotype is pushed into a more responsive zone of lowered proliferation. These data suggest 
that glucose is a key nutrient tied to BRAF inhibition, and PLX4720 efficacy is maximized in 
glucose-limiting conditions.   
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Figure 4.7: Glucose Affects PLX Response. Un-scaled heatmap of the proliferative responses 
of cell lines treated in PLX4720 dose-response assay coupled with varying glucose 
concentrations (indicated in legend, 5 glucose/media conditions total). The doses of PLX4720 
are the x-axis (10 doses, from 32 µM to zero/DMSO) and concentrations of glucose are the y-
axis (from 25 mM to 1.55 mM, labeled using legend key). Data shown are from a single 
experimental run; experiment has been repeated at least once with similar results. 
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To test the hypothesis that increased glycolytic dependence is functionally related to 
enhanced PLX4720 response, we generated rho0 variants of two of our melanoma lines, A2058 
and WM164.  These two lines were chosen because they represented the least and most sensitive 
lines, respectively, to PLX4720 in our assays.  Generating rho0 variants (which lack 
mitochondrial DNA and, thus, lack a functional electron transport chain) allowed assurance of a 
quantitative shift to an exclusively glycolytic metabolic program.  We confirmed depletion of 
mitochondrial DNA (data not shown) and showed absence of mitochondrial oxygen consumption 
and a significant increase in glycolytic rate combined with a significantly decreased glycolytic 
reserve (Figure 4.8) compared to the parent line for each variant.   
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Figure 4.8: Metabolic Phenotype of Rho0 Variants. Extracellular pH or acidification rate of 
parental A2058 and WM164, and their Rho0 derived counterparts; bar plot showing maximum 
ECAR after adding glucose (10 mM), with t-test between parental and Rho0. Oxygen 
consumption rate of parental A2058 and WM164, and their Rho0 derived counterparts; bar plot 
showing maximum OCR after adding FCCP (1 µM), with t-test between parental and Rho0. Data 
shown are from a single experiment with 5-6 technical replicates; experiment has been repeated 
at least twice with similar results. Error bars are standard deviation. 
 
Rho0 cells have been shown to be capable of apoptosis (Kukat, Kukat, et al., 2008; 
Gregoire, Morais, et al., 1984) and are largely reported as carrying “ghost” mitochondria that 
lack electron transport chain functionality. Using the rho0 cells as a model, we tested whether 
forced glycolysis impacts response to BRAF inhibition by treating the rho0 variants with 
increasing doses of PLX4720. We first noted that, as might be expected, the overall proliferative 
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rates of the rho0 cells were decreased compared to their parental counterparts (Figure 4.9). 
However, even taking this into account, the percent inhibition (based on the final population 
doublings) with PLX4720 treatment was significantly increased in the A2058 & WM164 Rho0 
cells compared to their parental cell lines (Figure 4.9). 
	
	  
Figure 4.9: Rho0 Cells Have Increased Inhibition. Log2 normalized proliferation of parental 
A2058 treated with DMSO or 32 µM PLX4720, and Rho0 A2058 treated with DMSO or 32 µM 
PLX4720 (purple). Similar population doublings-time plot of WM164 (lower panel), with 
additional dose of 1 µM PLX4720. (D & E) Quantification of percent decrease in Doublings 
from respective DMSO control (ie., parental compared to parental, or Rho0 compared to Rho0). 
Data shown are from a single experiment with technical duplicates; experiment has been 
repeated at least twice with similar results. Error bars are standard deviation. 
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Anti-retrovirals Can Be Repurposed To Target BRAF-Mutated Melanomas 
Finally, we sought to replicate these findings and to force glycolysis using an alternative 
method with greater translational potential than ethidium bromide treatment. To accomplish this, 
we utilized the FDA-approved antiretroviral drug zalcitabine, also called ddC, in our cell lines. 
Zalcitabine/ddC is a nucleoside analog utilized as a first generation antiretroviral in the treatment 
of HIV (Lee, Hanes, and Johnson, 2003), falling out of favor largely due to the mitochondrial 
toxicities it exerted on various tissues and organs and the development of less toxic and more 
effective antiretrovirals (Birkus, Hitchcock, and Cihlar, 2002; Dalakas, Semino-Mora, and Leon-
Monzon, 2001). In humans, ddC has been shown to deplete mitochondrial DNA (Reiss, Casula, 
et al., 2004; Walker, Bauerle, et al., 2004), and in vitro assays have been utilized with up to 300 
µM ddC (Birkus, Hitchcock, and Cihlar, 2002), with efficient mtDNA depletion typically 
observed at concentrations in the 10-50 µM range. In our melanoma cell lines, treatment with 40 
µM ddC phenocopied the suppression of mitochondrial oxygen consumption, the increase in 
glycolysis, and the reduction in glycolytic reserve (Figure 4.10) seen in the rho0 cell lines.  
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Figure 4.10: Anti-retrovirals Can Deplete mtDNA. (Upper) Extracellular pH or acidification 
rate of parental A2058 and WM164, and their ddC/zalcitabine treated counterparts (40 µM 
zalcitabine); bar plot showing maximum ECAR after adding glucose (10 mM), with t-test 
between parental and ddC treated cells. (Lower) Oxygen consumption rate of parental A2058 
and WM164, and their ddC/zalcitabine treated counterparts (40 µM zalcitabine); bar plot 
showing maximum OCR after adding FCCP (1 µM), with t-test between parental and ddC 
treated cells. 
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Utilizing our previous model for in vitro assays (Harris, Frick, et al., 2016), we found the 
PLX4720 response in ddC-treated WM164 was significantly increased: the proliferative kinetics 
phenocopied the prior WM164 rho0 experiments and the percent decrease in doublings was 
statistically significant (Figure 4.11, upper). In contrast, the PLX4720-resistant line A2058 was 
more substantially affected by the attenuation of proliferation associated with ddC treatment 
itself: the percent decrease in doublings was not significant. However, the effect on proliferative 
kinetics of a single ddC treatment phenocopied the high-dose PLX4720 treatment (Figure 4.11).   
		 	
	 	
 
Figure 4.11: Figure legend on next page. 
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Figure 4.11: Anti-retroviral Effects On Proliferation. Left: Log2 normalized proliferation of 
ddC treated WM164 or ddC treated A2058. Right: Quantification of percent decrease in 
Doublings from respective DMSO controls for the cell lines (not statistically significant). Data 
shown are from a single experiment with technical duplicates; experiment has been repeated at 
least twice with similar results. Error bars are standard deviation. 
Moreover, ddC treatment in A2058 reduced the EC50 for PLX4720 ten-fold and also 
substantially reduced Emax (Figure 4.12, upper), both effects consistent with significantly 
enhanced efficacy of PLX4720 in the context of ddC pretreatment.  Additionally, the rate of 
proliferation affected the dose-response slopes, or Hill coefficients, revealing that ddC treatment 
decreased the Hill slope metric (Figure 4.12, lower). 
		
	 	
Figure 4.12: Anti-retrovirals Shift Dose Dynamics With BRAF Inhibition. Upper: Drug 
Induced Proliferative (DIP) metric dose response curves (non-normalized) marking model 
estimated EC50 values in nM (red dashed vertical line), and model estimated Emax values (grey 
dashed horizontal line). Lower: Non-normalized (bottom left) and normalized (bottom right) 
dose-response curves of A2058 parental and A2058 pre-treated with ddC/Zalcitabine. 
 
-8 -7 -6 -5 -4
[plx4720], log10 M
DI
P 
ra
te
, d
ou
bl
in
gs
 h
−1
-0
.0
2
0
0.
02
0.
04
EC50 =
109000 nM
Emax = 0.0228
A2058 
-8 -7 -6 -5 -4
[plx4720], log10 M
DI
P 
ra
te
, d
ou
bl
in
gs
 h
−1
-0
.0
2
0
0.
02
0.
04
EC50 =
11400 nM
Emax = 0.0104
A2058+40	µM	
Zalcitabine 
	 66	
Mitochondrial respiration provides more than just ATP through oxidative 
phosphorylation, as rho0 cells and electron deficient cells can still proliferate if provided uridine 
and pyruvate (King and Attardi, 1989; King and Attardi, 1996a; King and Attardi, 1996b). To 
test whether increased PLX4720 sensitivity in the ddC –treated A2058 might be due to a 
deficiency in the necessary biosynthetic intermediate aspartate, which is normally produced 
through mitochondrial respiration (Sullivan, Gui, et al., 2015; Birsoy, Wang, et al., 2015), we 
supplemented both pyruvate and exogenous aspartate to attempt to rescue the ddC-treated A2058 
cells.  Not only did this not rescue the proliferative response, proliferative rates were actually 
further decreased upon treatment with PLX4720 (Figure 4.13).  
 
Figure 4.13: No Rescue From Aspartate Nor Pyruvate During BRAF Inhibition. Log2-
normalized proliferation of parental A2058 (top left plot) and pre-treated ddC/zalcitabine A2058 
(remaining 3 plots, pre-treated with 40 µM of zalcitabine for ~5 days). 10 mM Aspartate (bottom 
left) or 10 mM Sodium Pyruvate (bottom right) was added to the medium. Data shown are from 
a single experiment with technical duplicates. 
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Discussion: 
 All cells, including tumor cells, have basic energy and metabolic needs for survival and 
proliferation. Cellular responses—such as adaptation, differentiation, proliferation, and signal 
transduction—are inherently complex and dynamic in nature. Therefore, sustained proliferation 
in the presence of targeted inhibitors is likely shaped by a cell’s dynamic metabolic constraints. 
In our study we investigated whether there exists a direct link between overall metabolic 
program and sensitivity to targeted BRAF inhibition, and if that relationship could be exploited 
to increase sensitivity in the cells. Our results demonstrate over-reliance on glycolysis can 
sensitize BRAF-mutated melanoma cells to targeted BRAF inhibitor treatment. The cells had 
significantly reduced proliferation (even death) when co-treated with PLX4720 and zalcitabine. 
This finding is in agreement with earlier reports (Haq, Shoag, et al., 2013; Hall, Meyle, et al., 
2013) suggesting mitochondrial inhibitors like oligomycin would be therapeutically beneficial in 
this cancer type. However, the use of oligomycin in humans would be difficult due to its extreme 
toxicity, and other mitochondrial inhibitors, like metformin and phenformin, probably exert 
antitumor effects but have potential dosage issues (Chandel, Avizonis, et al., 2016) and lactic 
acidosis problems (Shitara, Nakamichi, et al., 2013), respectively.  Antiretrovirals like 
zalcitabine, in contrast, have toxicities that may be easier to manage, and the portfolio of 
nucleoside analogs has been greatly expanded compared to the clinically available mitochondrial 
inhibitors (Lee, Hanes, and Johnson, 2003; Dalakas, Semino-Mora, and Leon-Monzon, 2001). 
Moreover, there is a tremendous amount of clinical experience with antiretrovirals used alone, in 
combinations, and in the context of many other drugs. The dose of ddC used in our studies is 
admittedly high in comparison to plasma concentrations typically achieved with conventional 
dosing to treat HIV infections, though our timeframe for treating cells to achieve mtDNA 
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depletion was also very short. In translating these findings to in vivo studies, lower doses of ddC 
for longer periods of time would be expected to produce the same effects while allowing 
toxicities to remain manageable. The DIP rate metric overcomes time-related biases of slow 
acting vs. fast acting drugs, fast vs. slow-proliferating cells, and complex contributions of cell 
death and division that plague typical end-point assays. Interestingly, though, the Hill slope (or 
Hill coefficient) emerges as an important metric for evaluating antiretrovirals in the context of 
cancer therapeutics, and it has already been postulated by others to be clinically important when 
assessing drug sensitivity in the context of non-genetic influences (Fallahi-Sichani, Honarnejad, 
et al., 2013).  Moreover, as a consequence of “washing out” time-dependent biases, the DIP rate 
metric may miss potentially clinically meaningful findings.  This can be seen with ddC treatment 
of A2058, where a major effect of high dose, short duration ddC treatment is to slow 
proliferative rate.  This is problematic for DIP rate-based assessments, but clinically, a slower 
growing tumor would generally be regarded more favorably than a rapidly growing one.  
Moreover, DIP rate analysis alone would miss the 10-fold shift in the EC50 for PLX4720 in 
ddC-treated A2058.  Should this effect translate fairly directly into in vivo studies, this would 
represent a shift of EC50 for BRAF inhibitor from outside the typically achievable range into a 
dose range that is readily achievable and that may allow for lower doses to limit toxicities.    
However, there still remain questions about what physiological role glycolysis, oxidative 
phosphorylation, or the mitochondria play for BRAF-mutated melanomas, particularly under the 
context of drug treatment.  It can be speculated that BRAF inhibition cuts off the oncogenic 
signaling that is ramping up the metabolism and ATP production. ATP hydrolysis and glucose 
flux have been postulated to be intimately linked in highly proliferative cells: the ATP/AMP 
ratio is repressed and kept to a minimum by linking high ATP consumption activities (like N-
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glycosylation and folding of proteins (Fang, Shen, et al., 2010)) with increased glycolytic flux 
for biosynthetic production. Thus, the high amounts of ATP generated from glycolysis are 
shuttled in order to relieve negative feedback inhibition on major glycolysis enzymes such as 
PFK.  Other mechanisms to control ATP/AMP levels involve the tumor suppressor LKB1 and its 
target the AMP-activated Kinase: loss of function mutations and deletions of LKB1 in non-small 
cell lung cancers (Whang, Park, et al., 2016) and Peutz-Jeghers Syndrome (Beggs, Latchford, et 
al., 2010), and activating mutations in PI3K and AKT that lead to strong signaling increasing 
glycolytic flux and ATP (and thus preventing the activation of AMPK through high levels of 
AMP) (Hardie, 2004; Shaw, Kosmatka, et al., 2004; Schaffer, Levin, et al., 2015).  In BRAF-
mutated melanomas it has been shown that the strong signaling down the MEK-ERK-RSK 
pathway enables negative regulation on LKB1 through phosphorylation of S325 and S428 sites 
(Zheng, Jeong, et al., 2009).  Interestingly, WT BRAF immuno-precipitates with AMPK (Shen, 
Yuan, et al., 2013) and high phospho-ERK staining inversely correlated with low phospho-
AMPK staining in vivo under the context of WT BRAF (Shen, Yuan, et al., 2013). To put these 
finding into context WT BRAF uses AMPK in the context of integrating energy metabolism with 
proliferation; mutant BRAFV600E will dampen the influence of AMPK, possibly because it is not 
needed for downstream metabolic signaling.  BRAF inhibition may relieve the negative feedback 
regulation on LKB1 and thus, provide an avenue of metabolic rescue that would include 
mitochondrial biogenesis to make up for the resultant diminished ATP production. Therefore, in 
our work when we targeted mitochondrial DNA and rendered the cells functionally deficient, we 
metabolically constrained the cells to rely on glycolysis for all ATP (and redox regeneration). 
Our approach of targeting differential tumor metabolism represents a break from previous 
models constrained within the more narrow scope of looking upstream and downstream along 
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the RAS-RAF-MEK-ERK signaling axis. Identifying avenues of resistance through “non-
oncogenic vulnerabilities” has been suggested (Adler and Gough, 2011; Singh, Joshi, and 
Komurov, 2015), particularly since many cancers are multifaceted and resistant to single target 
therapies. The functional integration of drug resistance mechanisms leads to adaptive, 
independently actionable phenotypes. Targeting the metabolic phenotype rather than a single 
genetic driver appears promising: the phenotype sustains the tumor--not necessarily the pathway, 
due to signaling plasticity and mechanistic redundancies. Thus, the benefit of targeting a terminal 
phenotypic state and bypassing the risk of oncogene switching or secondary mutations can be 
realized with current FDA-approved drugs such as zalcitabine. The strength of this study is that 
we used a large panel of cell lines, treated with physiologically relevant doses of the BRAF 
inhibitor PLX4720.   
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CHAPTER V 
 
DYSFUNCTIONAL MITOCHONDRIA LEADS TO A NON-QUIESCENT IDLING 
STATE IN DRUG TREATED BRAF MUTATED MELANOMA CELLS 
 
Adapted From: Paudel BB, Harris LA, Hardeman KN, Abugable A, Lizama-Manibusan B, 
McLaughlin BA, Tyson DR, Fessel JP, and Quaranta V. “Dysfunctional Mitochondria Leads To 
A Non-quiescent Idling State In Drug Treated BRAF Mutated Melanoma Cells.” (In Preparation 
To Be Submitted Spring of 2017) 
 
Abstract: 
Therapeutic resistance to targeted, small molecule inhibitors remains a clinical challenge 
for melanoma patients with the BRAF-V600 mutations. We sought to understand the 
proliferative dynamics of these cancer cells during the course of treatment, and utilized a battery 
of in vitro assays to illuminate cellular responses. We found that exposure of BRAF-mutated 
melanoma cells to BRAF inhibitors induces complex, non-linear proliferation dynamics followed 
by transition into a non-quiescent state of balanced death and division that we term “idling” state. 
Experiments with single cell-derived clonal lineages suggest that the response dynamics are a 
combined effect of clonal selection and drug-induced reversible phenotypic state transitions. Our 
results indicate that previously reported differences in cell line sensitivity to BRAF inhibitors are 
misleading, as they only occur on short time scales and dissipate ~100 hours after drug addition. 
Instead, all cell lines that we tested, including clonal isolates, transition into the idling state in the 
presence of continued BRAF inhibition. Interestingly, this idling state has features of 
	 72	
significantly decreased metabolism, and poor mitochondrial function despite prior up-regulation 
of PGC1α. Because of the continued division observed at the single-cell level, idling melanoma 
cells are potential reservoirs for genetic mutations and may represent an untapped phenotypic 
bottleneck susceptible to therapeutic targeting. My contribution to this developing manuscript is 
with data acquisition at the population level (Figures 5.1, 5.3, 5.4) and phenotypic 
characterization of the subclones in regards to metabolism (Figures 5.5 and 5.6). Presently, I am 
working with the first author to develop final key experiments to finish the manuscript and 
submit to a peer-reviewed journal. 
Introduction: 
Targeted small molecule inhibitors of BRAF (Flaherty, Yasothan and Kirkpatrick, 2011) 
show remarkable, short-term efficacy in melanoma patients with tumors harboring BRAFV600 
mutations (Flaherty, Puzanov, et al., 2010; Chapman, Hauschild, et al., 2011). However, clinical 
responses are variable, short-lived, and tumor recurrence is almost universal within a few months 
of initiation of therapy (Chapman, Hauschild, et al., 2011; Sosman, Kim, et al., 2012). 
Overcoming inherent and acquired resistance to targeted therapy is a major goal of current 
melanoma research, which uncovered two categories of resistance mechanism: (i) re-activation 
of mitogen-activated protein kinase (MAPK) signaling cascades (Poulikakos, Persaud, et al., 
2011; Montagut, Sharma, et al., 2008; Wagle, Emery, et al., 2011; Shi, Moriceau, et al., 2012; 
and Villanueva, Vultur, et al., 2010), and (ii) activation of MAPK-pathway independent 
signaling pathways (Wagle, Emery, et al., 2011; Nazarin, Shi, et al., 2010; Shi, Hugo, et al., 
2014; Rizos, Menzies, et al., 2014; and Whittaker, Theurillat, et al., 2013). This has led to the 
development of combination therapies of BRAF inhibition with other targeted agents (Larkin, 
Ascierto, et al., 2014; Menzies and Long, 2014; Greger, Eastman, et al., 2012; Long, 
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Stroyakovskiy, et al., 2014; Flaherty, Infante, et al., 2012; and Whittaker, Cowley, et al., 2015) 
or in conjunction with immunotherapy (Hu-Lieskovan, Robert, et al., 2014). While these 
therapies improve clinical responses, variation in treatment outcomes persists and benefits 
remain transient and unpredictable (Long, Stroyakovskiy, et al., 2014). 
 
Most of our knowledge of melanoma tumor recurrence is derived from analysis of post-
resistant tumors or cells (Rizos, Menzies, et al., 2014); the proliferation dynamics of drug-treated 
tumor cells prior to resistance is poorly understood (Smith, Brunton, et al., 2016). Resistance is 
usually attributed to rare, resistance-conferring genetic alterations that either preexist (Greaves 
and Maley, 2012; Shackleton, Quintana, et al., 2009; and Nowell, 1976) or develop during 
therapy (Shi, Hugo, et al., 2014; and Johnson, Menzies, et al., 2015). However, there is 
accumulating evidence that non-mutational processes play a significant role in the response of 
cancer cells to drug treatment (Smith, Brunton, et al., 2016; Raj and van Oudenaarden, 2008; 
Vandamme and Berx, 2014; Niepel, Spencer, and Sorger, 2009). It has been suggested that 
cancer cells employ a dynamic survival strategy involving phenotypic state transitions, governed 
by epigenetic alterations to evade lethal external cues (Sharma, Lee, et al., 2010; and Hugo, Shi, 
et al., 2015). These observations are consistent with preclinical and clinical evidence suggesting 
that cancer cells can become re-sensitized to therapy after a brief “drug holiday” (Sun, Wang, et 
al., 2014; Das Thakur, Salangsang, et al., 2013; and Cara and Tannock, 2001). It is likely, 
therefore, that both genetic and non-genetic processes are involved in the acquisition of drug 
resistance and/or relapse of melanoma tumors. 
Here, we use experimentation to quantify drug-induced proliferation dynamics in 
numerous BRAF-mutated melanoma cell lines at the cell population, clonal, and single cell 
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levels. We show that treatment with a BRAF inhibitor induces entry into a previously 
unrecognized, non-quiescent state of balanced death and division (zero net growth), which we 
refer to as the “idling” state. Experiments with single cell-derived clonal lineages suggest that the 
drug-response dynamics are a combined effect of clonal selection and drug-induced phenotypic 
state transitions. We postulate that idling cancer cells may constitute a reservoir from which 
genetic mutations and, ultimately, tumor recurrence arises. They may also represent a previously 
unappreciated phenotypic bottleneck that can be targeted, and perhaps eliminated, with an 
appropriate secondary treatment. 
Results: 
To investigate drug-induced proliferation dynamics of BRAF-mutated melanoma cells to 
BRAF inhibition, we subjected populations of the BRAF-mutated human melanoma cell line 
SKMEL5 to varying concentrations of a small molecule BRAF kinase inhibitor (BRAFi) called 
PLX4720. Using fluorescent time-lapse imaging, we tracked cell numbers over time for a period 
of approximately two weeks. For intermediate drug concentrations, we observed complex, non-
linear population dynamics (Figure 5.1). After an initial transient period (~24 hours), the cell 
population regressed significantly (for ~24 hours), rebounded (for ~100 hours), and then settled 
into a phase of near zero net growth. We confirmed that the zero-net-growth phase is not trivially 
due to confluency (data not shown). In addition, some cells (~10%) are positive for an 
exogenous marker of the S, G2, and M phases (Figure 5.1, part B), indicating continuing 
progression through the cell cycle, while other cells exhibit early nuclear morphological changes 
associated with apoptosis (Ziegler and Groscurth, 2004) (data not shown). Since cells continue to 
turnover (die and divide) but the cell population maintains a constant level, we refer to this phase 
as “idling”. Furthermore, the idling phenotype is not specific to SKMEL5 cells; we also observe 
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it in A375, SKMEL19, SKMEL28, WM164, WM793 and WM88 cell lines (Figure 5.1, part C). 
Idling cells resume normal proliferation when switched to drug-free media and exhibit similar 
initial proliferation dynamics when re-challenged with the drug (Figure 5.1, part D), suggesting 
that the idling phase is both drug-induced and reversible. Taken together, these results indicate 
that entry into an idling phase in response to continued long-term BRAF inhibition is a general 
characteristic of BRAF-mutated melanoma cells. 
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Figure 5.1: BRAF-Mutated Melanoma Cell Populations Idle Under Continued BRAF 
Inhibition. (a) Population growth curve (log2 normalized) for the SKMEL5 parental cell line 
treated with BRAFi. (b) Percentage of FUCCI-positive cells during 168-300h of BRAFi 
treatment for the SKMEL5 parental cell line. (c) Population growth curves for six additional 
BRAF-mutated melanoma cell lines in BRAFi. Mean responses are shown as solid lines, 95% 
confidence intervals as shaded regions. All results are based on 3+ technical replicates. (d) Idling 
cells respond similarly to BRAFi as drug-naive cells after a 24h drug holiday: (left) Population 
growth curves (log2 normalized) for drug-naive and post-idling SKMEL5 cells in complete-
growth media; (right) Responses of drug-naive and post-idling cells to 8µM BRAFi. 
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We investigated more closely the short-term, non-linear population dynamics in the 
SKMEL5 cell line. We sought to determine whether all cells were adapting to BRAFi or whether 
the population-level response was a composite of clonal subpopulation responses, i.e., clonal 
selection (Nowell, 1976). To test these possibilities, we tracked ~200 single cell-derived colonies 
(~110 cells per colony) treated with BRAFi using the Clonal Fractional Proliferation (cFP) assay 
(Frick, Paudel, et al., 2015). Drug responses varied from clone to clone and encompassed a broad 
range of behaviors, from rapidly expanding to rapidly regressing (Figure 5.2, parts A and B). 
Further, the proliferation rate of a clonal lineage prior to treatment does not correlate to its 
proliferation rate in response to BRAFi (Figure 5.2, part C). The aggregate of the clonal 
responses qualitatively matches the short-term population-level response (Figure 5.2, part D), 
suggesting that the short-term dynamics are a result of clonal selection: the initial regression 
phase is due to depletion of the proportion of the population with negative proliferation rates and 
the subsequent rebound is due to expansion of positively proliferating clones. Similar results 
were obtained for other drug concentrations (data not shown). Moreover, to determine whether 
clonal heterogeneity is a general phenomenon, we tested two other BRAF-mutated melanoma 
cell lines in BRAFi and observed similar clonal variation in drug response (data not shown). 
Together, these results indicate that BRAF-mutated melanoma cell populations contain pre-
existing hidden clonal heterogeneity that is revealed upon drug-exposure and shapes drug-
response population dynamics in the short term. 
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Figure 5.2: Short-Term Drug Response is Due to Clonal Heterogeneity. (a) Population 
growth curves (log2 normalized) for BRAFi-treated SKMEL5 single cell-derived colonies 
(n=203) obtained using the cFP assay. (b) Distribution of clonal proliferation rates of single cell-
derived clones in BRAFi, quantified by linear fit to the response dynamics (d) Comparison of 
untreated and BRAFi-treated (8µM) proliferation rates (doublings/h) for SKMEL5 single cell-
derived colonies (n=203) obtained using the cFP assay. (d) Comparison of the clonal composite 
(sum of cell counts from all colonies at each time point) to the SKMEL5 population-level 
response (means are shown as solid or dashed lines, 95% confidence intervals as shaded regions; 
the population-level response is the same data as in Figure 5.1, part A). 
 
To reconcile the long-term population-level response (Figure 5.1) with the observed 
clonal heterogeneity (Figure 5.2), we sought to determine whether each clonal lineage enters an 
idling phase or whether only select clones do. To distinguish between these possibilities, we 
isolated over a dozen single cell-derived sublines from the SKMEL5 cell line. Upon exposure to 
BRAFi, the short-term dynamics (<100h) varied significantly across the clonal sublines, with 
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some expanding, some regressing, and some maintaining a stable population. We selected three 
sublines representative of the range of observed short-term responses for further 
experimentation: SC01 (expanding), SC07 (stable), SC10 (regressing). Upon prolonged exposure 
to BRAFi, despite their initial divergent responses, both SC01 and SC10 converged to 
approximately zero net growth, while SC07 maintained its initial zero-net-growth response 
(Figure 5.5, part A). In each case, we confirmed that entry into the idling phase is not due to 
confluence (Figure 5.3).  
 
Figure 5.3. Plate Confluency Is Not Responsible For Idling Phase. Representative 
microscopy images at 190 hours with treatment of DMSO or 8 µM PLX4720. Cells are stained 
with Hoeschst stain (blue), and the image is overlayed with FUCCI-positive cells in green 
channel.  The cell lines SC01, SC07, SC10 are single cell-derived sublines from the melanoma 
cell line SKMel5 (See text in this Chapter V for additional details, first paragraph page 79). Data 
shown are from a single experiment with technical replicates. 
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By manually tracking the fates of multiple individual cells over time, we also determined 
that all three clonal sublines experience both death and division events while in the idling phase 
(Figure 5.4, part B), confirming that idling is not due to quiescence but rather to balanced rates 
and death and division (concurrent death and division are also observed in the early response, 
data not shown). Together, these results suggest that idling is a phenotypic state that all clonal 
populations, regardless of initial sensitivity, can transition into in the continued presence of 
BRAF inhibition. 
To determine whether the idling state could be targetable, we re-challenged (following a 
brief 24h drug holiday) idling cell populations of three clonal sublines (SC01, SC07, and SC10) 
with Trametinib (a MEK inhibitor), Cisplatin (a platinum-based chemotherapeutic), BEZ235 (a 
PI3K/mTOR dual inhibitor), and BKM120 (a PI3K inhibitor). Sensitivity to the PI3K inhibitors 
did not change in the idling cells as compared to their untreated counterparts. In contrast, idling 
cell populations of clonal sublines SC07 and SC10 acquired sensitivity to Trametinib and 
BKM120 (Figure 5.4, part C). Idling SC07 cells were also sensitive to Cisplatin. These 
preliminary results indicate that transition into the idling state indeed opens additional potential 
treatment avenues. 
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Figure 5.4: Single Cell-Derived Clonal Sublines Idle Independent of Short-Term Dynamics. 
(a) Population growth curves (log2 normalized) for three single cell-derived SKMEL5 sublines 
treated with BRAFi (means are shown as solid lines, 95% confidence intervals as shaded 
regions; all results are based on 3+ technical replicates). (b) Single cell lifespans vs. birth times 
(time of first mitotic event) for the three sublines after a week in BRAFi. Cells born during the 
experiment but reaching the end of the experiment (EOE) without a second mitotic event are 
plotted along the diagonal. (c) Population growth curves (log2 normalized) for three single cell-
derived SKMEL5 sublines, either drug-naïve or following a week in BRAFi (“post-idle”), treated 
with trametinib, cisplatin and BKM120 (error bars are 1 standard deviation). For post-idle 
populations, BRAFi was removed less than 24h prior to subsequent drug addition. Data shown 
are from 3+ experiments. 
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BRAF inhibition might possibly relieve the negative regulation mutant-BRAF exerts on 
metabolic housekeeping strategies, via regulation of LKB1 (Zheng, Jeong, et al., 2009). 
Therefore, we decided to examine the global metabolism of the subclones, particularly the 
glycolysis and mitochondrial respiration using Glyco and Mito Stress Tests on the Seahorse 
Extracellular Flux Analyzer. Using sequential addition of metabolic inhibitors, we assessed the 
oxygen consumption and glycolysis (via lactate production) of the subclones in their basal (or 
untreated) and idling (7 days treatment with PLX4720) states. The untreated subclones have 
varying metabolic profile traces and it is interesting to note that the SC01 has little to know 
Glycolytic Reserve: after the three measurements of basal and glucose ECAR, the addition of 
oligomycin does not yield a subsequent increase in ECAR as it does in SC07 and SC10 (Figure 
5.5., lower left side). Surprisingly, we found a significant metabolic depression in the idling cells 
(Figure 5.5, right side) across all three subclones. Others have reported increased oxygen 
consumption rates (OCR) upon BRAF inhibition (Haq, Shoag, et al., 2013; Corazao-Rozas, 
Guerreschi, et al., 2013), so the substantially decreased OCR at basal and FCCP-stimulated 
levels is unexpected.  
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Figure 5.5: Prolonged BRAF Inhibition Causes Metabolic Depression. Upper: Oxygen 
consumption profiles for the cell lines with sequential additions of oligomycin (1 µM), FCCP (1 
µM) and Rotenone/Antimycin A (0.5 µM). Lower: Extracellular pH profiles for the cell lines 
with sequential additions of glucose (10 mM), oligomycin (1 µM), and 2-deoxyglucose (0.5 
µM). 
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Others have shown that mitochondrial biogenesis and a shift toward oxidative 
phosphorylation occurs in BRAF-mutated melanomas under PLX4720 treatment, so the prior 
result of decreased OCR led us to examine the mRNA expression of PGC1a. Looking at all three 
sublines (plus the parental cell line they were generated from), there is clear cessation of PGC1a 
expression over time, particularly after 120 hours of BRAF inhibition treatment (Figure 5.6). 
 
Figure 5.6: Increased PGC1a Levels Are Not Sustained. Using PCR, mRNA expression for 
each cell line is normalized to its own zero-hour time point. Relative expression is plotted with 
standard deviation (~2-3 replicates each time pt/cell line). SC01, SC07 and SC10 are single cell-
derived sublines from the melanoma cell line SKMel5 (See text in this Chapter V for additional 
details, first paragraph page 79). Parental= SKMel5 cell line. On the x-axis the time lengths for 
drug exposure are indicated (0, 72, 120, 192, and 240 hours). 
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Finally, we decided to examine more closely the mitochondrial physiology of the 
subclones. MitoOrange and MitoGreen MitoTracker fluorescent probes were used to stain and 
visualize the mitochondria of the three sublines. MitoGreen will stain the mitochondria of all live 
cells without regards to the mitochondrial membrane potential; thus, we used MitoGreen to see if 
mitochondrial mass was increased in the idling cells. The total mass of mitochondria appear to 
decrease on SC07, increase in SC10, and stay relatively the same in SC01 (Figure 5.7, left 
panel).  However, the average size of the mitochondria in SC10 appears to decrease significantly 
(Figure 5.7, middle panel) suggestive of mitochondrial fragmentation or fission. This led us to 
utilize MitoOrange CMTMR, which will only accumulate inside intact mitochondria that have 
retained their membrane potential. The overlap between MitoOrange and MitoGreen decreases 
significantly in the SC10 idling cells (Figure 5.7, right panel). These results indicate that the 
early increased expression of PGC1a does not lead to functional mitochondria in any of the 
sublines: SC07 actually decreases mitochondrial mass and SC10 exhibits signs of fragmented, 
damaged mitochondria. 
 
Figure 5.7: Mitochondrial Physiology Worsens Under Idling State. Plots of fluorescence 
intensity (left), size (middle, in arbitrary pixel units), and membrane potential per area (right).  
The cells were stained with MitoTracker MitoGreen (Ch1) and MitoTracker MitoOrange (Ch2). 
Basal indicates no drug treatment. Idling indicates cells exposed to 7 day PLX4720 treatment (8 
µM). SC01, SC07 and SC10 are single cell-derived sublines from the melanoma cell line 
SKMel5 (See text in this Chapter V for additional details, first paragraph page 79). 
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Discussion: 
We report here that sustained BRAF inhibition (>1 week) induces entry of BRAF-mutated 
melanoma cell populations into an idling state of balanced death and division, which results in 
~zero net proliferation. Idling occurs at both the population and clonal levels, independent of 
variation in initial short-term response, and is drug-induced and reversible, consistent with non-
mutational drug tolerance described in earlier reports (Smith, Brunton, et al., 2016). To our 
knowledge, the idling phenotype has not been previously described. We attribute this to the fact 
that drug response assays are usually performed over short observation times (72-96h) and 
proliferation rates are not usually measured (Tyson, Garbett, et al., 2012; Harris, Frick, et al., 
2016; Frick, Paudel, et al., 2015), as we do in this work.  
This indicates that previously reported differences in sensitivity among melanoma cell 
lines, measured on short time scale, might indeed be misleading. Our findings thus provide a 
unifying view of how BRAF-mutated melanomas respond to BRAF inhibition as well as a 
conceptual framework for how they might evade therapeutic interventions using both non-
mutational and mutational means. It is possible that idling cancer cells constitute the bulk of the 
stable disease (tumors neither increasing nor decreasing in size) observed in patients following 
targeted therapy and preceding tumor recurrence (Casanovas, Hicklin, et al., 2005). This view is 
consistent with previous reports speculating that drug-induced tolerant cancer cells act as 
reservoirs from which genetic mutation, and ultimately tumor recurrence, arises (Sharma, Lee, et 
al., 2010; Ramirez, Rajaram, et al., 2016; Hata, Niederst, et al., 2016; Menon, Das, et al., 2015; 
Lito, Rosen, and Dolit, 2013). However, in contrast to those reports, we show here that idling 
cancer cells continue active division. We speculate that continued progression through the cell 
cycle during idling makes cells prone to accumulating deleterious mutations and, hence, a more 
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fertile ground for acquired resistance than quiescent (Sharma, Lee, et al., 2010; Haass, Sproesser, 
et al., 2008; Haass, Beaumont, et al., 2014) or senescent cells (Haferkamp, Borst, et al., 2013). 
Therapeutic approaches that suppress or eliminate this non-quiescent reservoir of idling cells 
could thus delay, perhaps indefinitely, tumor recurrence. Our model assumes that in the idling 
phase the majority of cells occupy a state of zero net proliferation. If this is true, then idling 
constitutes a phenotypic bottleneck that may be targetable with an appropriate secondary 
treatment. Initial experiments show that indeed new drug sensitivities are acquired by idling 
cells, although each clonal subline behaves differently in this respect. Future studies should 
focus, therefore, on identifying the molecular signatures of idling cancer cells and developing 
therapeutic approaches to eliminate them.  
Many in the field have reached a consensus that some type of metabolic reprogramming 
in BRAF-mutated melanomas is occurring after therapy treatment: the details and the 
mechanism, however, remain unresolved. It was recently suggested that resistance to targeted 
BRAF inhibition requires two steps: first, a metabolic reprogramming during the early phases of 
treatment, then the acquisition of mutation(s) that will drive resistance, continued proliferation, 
etc. (Verduczo D, Flaherty KT, and Smalley, 2015).  In this context, the mitochondria play a 
very important role of managing the bioenergetics demands within the cell. As a critical 
biosynthetic powerhouse, the mitochondria coordinates and integrates metabolite signaling from 
the cytosol to help build fatty acids, nucleotides and amino acids (Ahn and Metallo, 2015). 
Therefore, mutations or alterations related to the mitochondria can be the driving metabolic 
trigger for reprogramming before a mutation event. Our finding of mitochondrial fragmentation 
and dysfunction thus explain the idling phenotype and provide motivation for a two-hit model.  
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Under treatment, subclone 10 undergoes mitochondrial fragmentation that accompanies 
the physiological dysfunction (reduced oxygen consumption). Fission of mitochondria is 
generally thought to be pro-tumorigenic, as targeting mitochondrial fission can decrease 
proliferation, cell cycle progression, and cell viability (Rehman, Zhang, et al., 2012; Arismendi-
Morillo, 2009; Chen, Dasgupta, et al., 2014; Inoue-Yamauchi and Oda, 2012; and Zhang, Jin, et 
al., 2013). Indeed, Kashatus and colleagues asked if “altering the balance of mitochondrial fusion 
and fission” could be targeted particularly in RAS mutated tumors, and demonstrated that MAPK 
signaling promotes mitochondrial fission via phosphorylation of Drp1 by ERK2 (Kashatus, 
Nascimento, et al., 2015). This brings the possibility of the SKMel5 clones, particularly subclone 
10, undergoing a type of Mitochondrial Dysfunction-associated Senescence (MiDAS), termed by 
Wiley and co-authors (Wiley, Verlarde, et al., 2016). 
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CHAPTER VI 
 
SUMMARY, CONCLUDING REMARKS, AND FUTURE DIRECTIONS 
 
Summary: 
Melanoma is the most malignant form of skin cancer and around 50% of melanomas 
harbor a specific mutation in the MAPK family member BRAF kinase, predominantly V600E or 
V600D (Davies, Bignell, et al., 2002; Ribas and Flaherty, 2011; Ascierto, Kirkwood, et al., 
2012). BRAF-targeted therapies like vemurafenib and dabrafenib have high response variability 
in patients, and the premise of this thesis work is to connect metabolic changes to response 
variability. Fortunately, there exist cell line models that could be used to test functional 
relationships of proliferative responses and intrinsic, cellular metabolism. Dysregulated 
metabolism has been shown to affect therapeutic responses, by influencing compensatory 
signaling, expanding proliferation, repressing apoptosis, and active/passive drug transport 
mechanisms. Interestingly, the main part of this thesis (Chapter IV) demonstrated that heavy 
reliance on glycolysis—with little to none Glycolytic Reserve—sensitizes cells for an increased 
response to targeted therapy. This result confirms early evidence of BRAF-mutated melanomas’ 
addiction to glycolysis and adaptation towards oxidative phosphorylation. Furthermore, this is 
the first phenotypic exploration on how the FDA-approved antiretroviral zalcitabine affects 
proliferation of the melanoma cells’ co-treated with vemurafenib. Figure 6.1 illustrates a 
schematic model of resistant, oxidative cells. 
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Figure 6.1: Model of Metabolic Phenotypic Resistance to BRAF Inhibition. Conceptual 
diagram visualizing how BRAF-mutated cells may become increasingly oxidative as a 
mechanism of resistance. 
 
Given the results confirming a functional interaction between glucose metabolism and 
PLX4720 response (Figures 4.6 and 4.7), we set out to probe the details of this interaction with 
respect to particular metabolic strategies.  Oxidative phosphorylation was inhibited at its terminal 
step using the ATP synthase inhibitor oligomycin (Appendices B and C), and lactate-producing 
glycolysis was inhibited at its terminal step using the lactate dehydrogenase inhibitor oxamic 
acid (Appendix D). Ordered and viewed according to the PLX4720 response spectrum (Figure 
4.1), PLX-insensitive cell lines are more resistant to LDH inhibition; this makes sense, as the 
PCA data suggested that PLX-insensitive cells have more Glycolytic Reserve and metabolic 
flexibility. Oxamic acid exhibited a fairly wide dose-response relationship with regard to cell 
proliferation in our cell line models.  By contrast, oligomycin had an almost binary effect, with 
melanoma lines being either extremely sensitive to every dose or tolerant of every dose with an 
identical DIP rate approximately ½ of their respective untreated control. This result, in 
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combination with the oxygen consumption results (Figure 4.3), suggests that variable ATP-
linked respiration only translates to 2 proliferative outcomes: extreme sensitivity or adaptable 
tolerability. These data suggest that forcing a glycolytic metabolic strategy in the context of 
PLX4720 treatment may enhance the antitumor effect of mutated BRAF inhibition in relatively 
insensitive lines like A2058 and WM115. 
As detailed in Chapter V, the dynamics and biology of drug-treated tumor cells prior to 
the observation of treatment failure or resistance is generally understudied. However, with 
powerful models such as single cell-derived subclones, we can attempt to dissect the variability 
and the dynamic biology occurring within the first stages of BRAF inhibition. Single cell-derived 
subclones are about as genetically similar as it can possibly exist; thus, their usage allows for a 
type of experimental control against the varied background constellation of mutations cancers 
typically bear. Nonetheless, we still can observe varied responses at the clonal level, adding 
credibility to the accumulating evidence that non-mutational, epigenetic processes influence the 
response of cancer cells to therapeutics (Smith, Brunton, et al., 2016; Raj and van Oudenaarden, 
2008; Vandamme and Berx, 2014; Niepel, Spencer, and Sorger, 2009). With this report on the 
idling cancer cells in Chapter V, I can easily see the link towards what clinicians deem stable 
disease: a period before resistance or recurrence is reported where the tumor neither increases 
nor decreases. A type of metabolic reprogramming in BRAF-mutated melanomas is likely 
occurring after BRAF inhibitor treatment, and the idling state is simply a reservoir where the 
cells are not only dynamically adjusting their oxidative phosphorylation and mitochondrial 
operations, but likely acquiring mutations that will help drive their metabolic recovery. 
 It is important to consider the value-added or contribution this body of work gives to 
the field of melanoma cellular biology. Thinking back to Meenhard Herlyn’s gene expression 
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analysis (Zhang, Frederick, et al., 2016), part of this work has given more resolution on the 
particular phenotype of glycolysis that makes some melanomas super-sensitive and responsive to 
BRAF inhibition. The key role of glycolytic reserve in determining the ability of a cell to 
overcome addicting oncogene inhibition (ie., BRAF inhibition) is an important discovery. 
Furthermore, the suggestion to use anti-retrovirals creates a clear translational path to repurpose 
those drugs in the treatment of these cancers. I am not alone in this thought process: the 
MITF/PAX inhibition screen that Smith et al. used led them to target melanomas with protease 
inhibitor anti-retrovirals (Smith, Brunton, et al., 2016).  Additionally, coupling a dozen metabolic 
metrics to build a PCA is unusual in the field: most Seahorse Bioanalyzer users do not assay and 
measure both Glyco and Mito Stress Tests in their systems. High-throughput metabolic analyses 
and nutrient screenings should become the norm and Gohil et al. suggest a great design/platform 
for such experiments: using either glucose- or galactose-containing media, they screened over 
3,000 compounds to find even modest, subtle shifts in metabolism (Gohil, Sheth, et al., 2010). A 
screening design such as this should be employed to find novel inhibitors that shift metabolism 
of BRAF-mutated melanomas. Of course, the assays should employ the more powerful DIP rate 
metric as detailed in Chapter III of this thesis. Gohil et al. used static metrics (number of cells 
remaining after 3 days) but the static dose–response curves can only separate and enrich for 
highly potent compounds (like the rotenone >> phenformin example in Chapter III). Efficacy is 
obscured or lost when examining static dose-response analyses.  All in all, the work described in 
this thesis dissertation provides an important contribution to response variability and assay 
development, the glycolytic biology in relation to BRAF inhibition, and a finer inspection of 
variability within a tumor. These findings help resolve discordant reports in the literature and 
link a targetable metabolic phenotype to cellular proliferation.  
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Concluding Remarks: 
 BRAF-mutated cells may be addicted to glucose, due to reducing equivalents (NADH) 
produced for redox balance and the production of the central metabolite acetyl-CoA from the 
pyruvate generated through glycolysis. Acetyl-CoA is a 2 carbon acetyl group (CH3CO) linked 
by a thioester bond to the vitamin derivative coenzyme A; the molecule is impermeable to 
membranes (except passive diffusion through nuclear pores) and acts as a central metabolite by 
linking glycolysis to oxidative phosphorylation, influencing functionality and stability of 
proteins from translation through post-translation, and participating in cell cycle/mitosis via 
histone acetylation (Pietrocola, Galluzzi, et al., 2015).  Histone acetylation is important to drive 
preferential gene expression of high target genes involved for cell proliferation, glycolysis, and 
to counter oxidative stress (Pietrocola, Galluzzi, et al., 2015). Acetyl-CoA is the sole donor or 
“obligate cofactor” for histone acetyltransferases, thus centering this metabolite in epigenetic 
processes. There is subcellular compartmentalization of Acetyl-CoA, and in the context of the 
mitochondrial matrix, the alkaline pH of the negatively charged matrix can allow for non-
enzymatically driven acetylation due to physiochemical properties of generated acetyl-phosphate 
intermediates (Kuhn, Zemaitaitis, et al., 2014). 
In regards to the reported glutamine dependency as a mechanism of resistance (Baenke, 
Chaneton, et al., 2015; Hernandez-Davies, Tran, et al., 2015), reductive carboxylation of 
glutamine happens frequently when glycolysis is blocked, hypoxic conditions arise or in the 
setting of mitochondrial defects. Glutamine dependence, therefore, is probably a bioenergetic 
strategy for BRAF-mutated melanomas to recover Acetyl-CoA. Upon transport into the cytosol 
from a carrier, glutamine is metabolized to glutamate, then the glutamate is transported into the 
mitochondria via the glutamate-aspartate carrier SLC25A13. Enzymes glutamate dehydrogenase 
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2 (GLUD2) or glutamic-oxaloacetic transaminase 2 (GOT2) metabolize glutamate into α-KG, 
which then goes into the TCA cycle backwards (reductive carboxylation) to make citrate. Citrate 
can leave the mitochondria by the transporter SLC25A1 and is metabolized to acetyl-CoA (and 
oxaloacetate) by the enzyme ATP citrate lyase (ACLY). Interestingly, AKT1 phosphorylates 
ACLY on Ser455 to increase its activity (Lee, Carrer, et al., 2014); thus, it can be argued that 
activation of AKT1 signaling can help drive a glutamine dependency under BRAF-treatment in 
the end-goal of generating and accumulating acetyl-CoA. A key question to address would be if 
we could rescue a metabolic catastrophe phenotype by using cell-permeable dimethyl α-
ketoglutarate. In like manner, the cell membrane impermeant nicotinamide adenine dinucleotide 
(NAD+) has a central role in cellular metabolism and it can be postulated that the inhibition of 
BRAF signaling may also disturb the reductive-oxidative balance in BRAF-mutated melanomas. 
Future Directions: 
The WNT pathway 
WNT5A can drive Beta catenin expression and metastasis in melanoma. Hoek, et al 
describes phenotype switching model where melanoma cells are “growing or going”: 
proliferating/dividing versus metastasizing or invading (Hoek, Eichhoff, et al., 2008). BRAF 
mutated melanomas with high levels of Beta catenin are more sensitive to apoptosis from BRAFi 
(Biechele, Kulikauskas, et al., 2012).  That same group later showed that WNT5A is increased in 
cell lines made resistant through chronic exposure to BRAF inhibitor PLX4720 (Anastas, 
Kulikauskas, et al., 2014).  
Utilizing a high-throughput approach I found interesting preliminary data regarding the 
WNT inhibitor, pyrvinium pamoate (PP). PP is an antihelminthic or parasitic inhibitor that 
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inhibits WNT pathway signaling via the activation of Casein Kinase 1-α (Thorne, Hanson, et al., 
2010; Li, Flaveny, et al., 2014).  Figure 6.2 shows the DIP rates of BRAF-mutated melanomas 
treated with PP alone or with combination of PLX4720. Several phenotypes can be discerned 
from the data: PP appears to have additive effects with PLX in WM2664 and SKMel5 cells; 
combination has no effect in WM88 and WM164; and, an interesting PLX-rescue phenotype is 
observed in A375 and WM1799. These results are very preliminary and due to the design of the 
screen and drug solubility issues, dose optimization has not been completed. 
 
 
 
Figure 6.2. Figure legend on next page. 
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Figure 6.2: Phenotypes of WNT Inhibition Varies. High-throughput result of pyrvinium 
pamoate alone (red line) and with 2 µM PLX combination (blue line). Non-normalized DIP rate 
(slope of proliferation, per hour) are plotted as IC50 dose curve response with 10-fold dilutions 
of pyrvinium. Source drug plates are made first using the Echo 550/555 by Labcyte.  Echo 
provides acoustic liquid transfer and distributes the drugs into target plates at 8X final 
concentration via acoustic wave in units of 2.5 nano-L droplets (these drug plates are kept in -80 
& sealed until needed; 50uL media added later when used). The Bravo by Agilent (Velocity 11) 
is used for automated pipette liquid transfer and serial dilutions on the morning of the 
experiment. The plates are housed in a Cytomat incubator that can hold up to 42 individual 
plates; every plate is barcoded and read by a barcode reader before each data acquisition. 
Utilizing only the inner 308 wells of the 384 plate, the drug dilutions are done in either duplicate 
or triplicate; takes about 10 mins to image ea plate on an ImageXpress Micro XL automated 
microscope imager from Molecular Devices, and data is acquired every 8-9 hrs. Each 
experimental run produces about 2.5-3.5 TB of data. The cell lines shown here are WM88 
(“88.pyrvinium”), WM2664 (“2664.pyrvinium”), A375 (“375.pyrvinium”), SKMel5 
(“SK5.pyrvinium”), WM1799 (“1799.pyrvinium”), and WM164 (“164.pyrvinium”). 
 
Nonetheless, it is not discouraging to see the variable responses to PP. In fact, another set 
of high-throughput data suggests that a strong differential response to WNT inhibition is 
correlated to the varying inherent metabolism of these cells.  Data from the Cancer Therapeutics 
Response Portal version 2.0 (CTRPv2) were downloaded and pharmacological data extracted. 
An intelligent string classifier is used to parse the accompanying annotation, and the drugs are 
divided and binned based on their mechanism of action. Out of nearly 550 drugs, groups such as 
“EGFR,” “Proteasome,” “PI3K,” “DNA damage,” etc. are created; this also includes a “WNT” 
group consisting of 2 drugs—JW-74 and CCT036477.  JW-74 (Broad Institute ID BRD-
K75664313) inhibits WNT signaling by stabilizing a component of the Beta catenin destruction 
complex (Stratford, Daffinrud, et al., 2014); CCT036477 (Broad Institute ID BRD-A22997170) 
targets a Beta catenin-mediated transcription complex (Mathur, Sehgal, et al., 2015). WNT 
inhibition significantly correlates to an unintuitive mix of the Seahorse metabolic parameters, 
thus highlighting a complex relationship of inherent cellular metabolism and WNT signaling.  
.  
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Figure 6.3: WNT Inhibition Correlates To Metabolic Parameters. PCA of IC50 data of 2 
WNT compounds, JW-74 and CCT03677, on y-axis versus and the first principle component of a 
linear combination of Seahorse metabolic parameters. IC50 data is from the CTRPv2. JW-74 
was tested at drug ranges of 0.002 µM to 66 µM; CCT036477 was tested at 0.001 µM to 33 µM. 
A normalization was done on the IC50 data in order to roughly compare all drugs together in 
groups.  
 
Lactate Dehydrogenase and Glycolytic Intermediates  
 Membrane potential Δψ and (ΔpH) can significantly affect the distribution of reduced 
forms of products, substrates, reactants, and mediators of electron transfer. Craig Thompson’s 
group just showed that an acidic pH promotes an unusual production of the stereoisomer L-2-
hydroxyglutyrate (L-2HG) via ‘ “promiscuous” reduction of the alternative substrate α-KG’ by 
lactate dehydrogenase (LDH) (Intlekofer, Wang, et al., 2017). LDH does not normally reduce α-
KG, but usually has pyruvate as a canonical substrate, producing lactate. The acidic pH results in 
a protonated form of α-KG that can stably bind LDH, and the resulting L-2HG stabilizes HIF1α 
and is a purported cellular adaptation to acidic environments or acidosis under normoxia for 
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highly proliferative cells (Intlekofer, Wang, et al., 2017). In our melanoma cell line models, 
A2058—the most insensitive BRAF-mutated cell line—loses its concentration-dependent 
response to PLX4720 when treated with the LDH inhibitor Oxamic acid (Figure 6.4).  It is 
intriguing to postulate that the inability of cells to make lactate may create a substrate and 
cytosolic pH bottleneck. 
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Figure 6.4: Oxamic Acid Constrains Proliferation Under BRAF Inhibition. Population 
doublings of cell line A2058 treated with BRAF inhibitor PLX4720 (left), varied Oxamic acid 
with constant 2 µM PLX (middle) and varied PLX with constant 12.5 mM Oxamic acid. Data 
shown are from a single experiment with technical duplicates; experiment has been repeated at 
least twice with similar results for single drug doses only (not combination conditions). Error 
bars are standard deviation. 
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It would be interesting to probe the dependency and flexibility of the cells lines on the 
three major oxidation substrates of the mitochondria: fatty acids, pyruvate, and glutamine. 
Dependency is defined as the absolute need of a carbon source for oxidation and usage; 
flexibility, on the other hand, is a measure of adaptability when inhibited from using a particular 
fuel source. The concept of creating Fuel Dependency and Fuel Flexibility analyses is relatively 
new (propelled by the works of Anne Murphy, Christian Metallo, Nika Danial, and others).  
Mitochondrial Inhibition  
 Mitochondrial DNA (mtDNA) have a high mutation rate, mostly due to poor 3 to 5 prime 
exonuclease activity of the polymerase gamma, the lack of protective histones, assault of ROS 
due to the close proximity to the ETC, and a unique exposure to an enrichment of xenobiotics—
the negative charge on the inner matrix-side of the membrane is needed to maintain membrane 
potential and ATP production, but it also encourages the accumulation of lipophilic cations like 
toxins and dyes. Lastly, it has been shown that p53 helps with the stability of the polymerase 
gamma, yet many cancers have mutant p53 (and about 10% of melanomas have a mutated p53).  
Given the crucial role oxidative phosphorylation and mitochondrial respiration plays in 
phenotypic resistance, I can imagine or postulate that combination BRAF inhibitors and anti-
retrovirals would bring about positive or favorable composite endpoints: decreased clinical 
worsening, categorical increase in functioning or quality of life, etc. However, the combination 
of mitochondrial and BRAF inhibitors is not trivial, as Livingston and colleagues point out: 
dabrafenib- or vemurafenib-treated patients with concomitant use of the mitochondrial inhibitor 
and anti-diabetic treatment metformin had no improved survival or response benefits in the 
BREAK-3 clinical trial data (Livingston, Swann, et al., 2015).  
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Evaluating the Role of ROS in the Context of PLX4720 Treatment 
Early in this thesis project I sought to dissect the relative contributions or importance of 
varied biology subsequent of mitochondrial inhibition. Specifically, targeting the mitochondria 
produces 3 broad conditions that can significantly affect downstream phenotypes such as 
proliferation: 1) decrease in in ATP production from oxidative phosphorylation; 2) decrease in 
biosynthesis through mitochondrial pathways (metabolites for lipid generation and protein post-
translational modifications); and 3) increase in ROS generation.  I sought to test in several ways 
the importance of ROS in our model system by attempting to answer 2 broad questions: 1) Is the 
response machinery used to handle or dispose of ROS defective in these cells? 2) Does PLX4720 
treatment significantly increase ROS in a manner that is detrimental to these cells (and thus 
amplified by combination with other metabolic inhibitors)? The data in the following two figures 
helped shape my thinking and steer my thesis work away from ROS studies, by essentially 
eliminating ROS as a sensitizer and/or modulator of BRAF inhibition.  
 
To answer the first question about the ROS machinery in BRAF-mutated melanoma cells, 
I designed an experiment to see if targeting proteins involved in disposal of ROS would give 
strong decreases in proliferation. Raj et al. reported a small molecule inhibitor called 
Piperlongumine that is selectively toxic to cancer cells (in vitro); even a breast cancer mouse 
model showed differential toxicity to cancer cells, as the other tissues in the mice showed no 
clinical signs of adverse effects (Raj, Ide, et al., 2011). The authors used a combination method 
of stable isotope labeling with amino acids (SILAC) and small molecule affinity beads (Ong, 
Schenone, et al., 2009) to show that piperlongumine binds to proteins involved in responding to 
oxidative stress like Glutathione S-transferase pi 1 (GSTP1) (Raj, Ide, et al., 2011). This drug 
	 102	
interacts with proteins like GSTP1 and CBR1 to yield the cellular phenotype of depleted total 
glutathione, protein glutathionylation and increased ROS (Adams, Dai, et al., 2012). 
Piperlongumine’s bioactivity is related to its chemical structure: it has multiple electrophilic sites 
and two crucial olefin moieties (C2-C3 & C7-C8) that are essential for its cellular toxicity and 
ROS elevation (these moieties have Michael acceptor functionalities where a nucleophilic 
species is added) (Adams, Dai, et al., 2012). Adams et al. proposed a model where glutathione is 
added to the C2-C3 site 1st because the C2-C3 is more electrophilic/potent than C7-C8. Secondly, 
the piperlongumine-glutathione adduct will bind to a glutathione binding protein on its 
glutathione side and the entire complex is stabilized by the 2nd Michael addition of a nucleophilic 
part of the protein reacting with the C7-C8 electrophilic site (Adams, Dai, et al., 2012). Based on 
work from Raj et al., we know that the increased ROS in cancer cells treated with 
piperlongumine is probably nitric oxide and hydrogen peroxide but not superoxide anion (Raj, 
Ide, et al., 2011).  Therefore, I treated two BRAF-mutated cell lines to varying concentrations of 
Piperlongumine—a typical dose-curve experiment—to see if differential proliferative responses 
would occur. SKMel5 and SKMel28 were the cell lines I used: at the time they had common 
media (DMEM/F12) as this was prior to the acquisition of WM lines from M. Herlyn and the 
transition to DMEM media for all cells lines. Additionally, these cells had vastly different 
response dynamics evident from their population growth curves, and preliminary single-cell 
tracking revealed SKMel5 to display dramatic cell death (deemed a “Death Burst” at the time) 
during treatment with PLX4720. Piperlongumine, however, had no differential effects between 
SKMel5 and SKMel28 (Figure 6.5, lower right panel). Trying to design a more specific 
experiment, I created a rescue experiment by first treating the cells with the Complex 1 inhibitor, 
Rotenone to find an IC50 value that would reduce proliferation but not kill too many cells (data 
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not shown). Then, I treated the cell lines with a combination of Rotenone (218 nM) and varying 
does of the general antioxidant N-acetylcysteine or NAC. I surmised that NAC should rescue or 
increase the proliferation rate and this would be evident in the growth plots (Figure 6.5, lower 
left panel). However, there was no rescue in the SKMel5 nor SKMel28 (data not shown).  The 
caveat of the NAC+Rotenone experiment is that Complex I respiration may not be important in 
these cells; thus there would be little ROS produced to demonstrate measurable rescue benefits 
with the addition of NAC. Indeed, oxygraph measurements of oxygen consumption revealed that 
Patient Derived Xenograft (PDX) models of BRAF-mutated tumor samples consumed very little 
oxygen until the Complex II substrate (succinate) is added (PDX #1218, kindly provided by Ann 
Richmond; data not shown).  Due to the complexity of ROS effects, I consulted with other 
experts and acquired samples of two reagents: mitoTEMPO and mitoEbselen. 
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Figure 6.5: ROS Does Not Modulate Proliferation In The Context of BRAF Inhibition. 
Population doublings of either SKMel5 or SKMel28 treated with indicated compound.  For Pre-
Treatment experiments (top-right and middle-right panels) the mEbselen or mTEMPO was 
added to the wells first (in the dose-dependent fashion) and allowed to incubate for 15 mins; the 
controls (PLX only or DMSO had nothing added to them). Afterwards, the media was aspirated, 
washed 1x with PBS gently, and then replaced with fresh media plus 8 µM PLX4720 (or 
DMSO). For the NAC+Rotenone and Piperlongumine experiments, additional drug doses were 
examined but not included in these graphs for sake of clarity. Data shown are from a single 
experiment with technical duplicates. 
  
mitoTEMPO and mitoEbselen are mitochondria-targeted antioxidants designed with 
classic triphenylphosphonium moiety that allows for concentration within the mitochondria 
(Daiber, Di Lisa, et al., 2015). Functionally, mitoTEMPO targets superoxide, and mitoEbselen 
targets hydrogen peroxide. I executed another rescue experiment but this time using a co- and 
pre-treatment design. Furthermore, I used PLX4720 as the putative ROS-producing perturbation: 
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since my initial questions revolved around the importance of ROS under the context of variable 
responses to BRAF inhibition, then the most convincing rescue would be in the context of BRAF 
treatment. There was no evidence of rescue in the SKMel5 nor SKMel28 (data not shown for 
SKMel28). This led to the final experiments of measuring ROS directly in the cell lines. Initially, 
the dye CellROX was used to stain ROS in 96-well plates, but despite including H2O2 and 
untreated controls, I experienced quantitation problems (data not shown). Thus, high-pressure 
liquid chromatography (HPLC) was employed to directly measure the ROS-dye product from the 
cells. Untreated and 8 µM PLX4720-treated cells (48 hr treatment) were incubated with 1 µM 
MitoSOX for 20 mins right before analysis. MitoSOX, or hydroethidine, is a mitochondria-
targeted probe that reacts with superoxide to generate the red product 2-hydroxyethidium or 
dihydroethidium (Zielonka and Kaylanaraman, 2010). The prior experiment with CellROX was 
thought to be confounded due to quantitation problems with the microscope but also the 
generality of CellROX acting in the cytosol. Thus, probing with MitoSOX and HPLC 
quantification was intended as a more refined and targeted approach.  48 hours of treatment with 
8 µM PLX4720 did not result in a statistically significant difference from the DMSO controls; in 
fact, it was surprising to observe a trending decrease of superoxide formation (Figure 6.6.) 
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Figure 6.6: PLX4720 Does Not Form Differential Superoxide in BRAF-mutated Melanoma 
Cells.  HPLC (used in conjunction with fluorescence detection for robust quantitation) on 
Shimatzu HPLC system with temperature control and automated sampling.  Reverse-phase 
HPLC is done on a C18 column (Nucleosil 250 to 4.5 mm) and a mobile phase containing 0.1% 
trifluoroacetic acid and an acetonitrile gradient (from 37% to 47%). Results are normalized and 
reported based on protein concentration; all done in triplicate, error bars are SEM. Analysis 
provided by Sergey Dikalov and Alfiya Bikineyeva.  
  
Even though MitoSOX can be sequestered and concentrated in the mitochondria by ~500 
fold in comparison to cytosol, the probe has two significant limitations: interference from heme 
enzymes, cytochrome c and peroxidases (Zielonka and Kaylanaraman, 2010), and the similarly 
fluorescent waste product, ethidium (Dikalov and Harrison, 2012).  It is still unclear what role 
ROS plays in defining or shaping the variability found in BRAF-mutated melanoma cell lines, 
however these initial experiments can help lay groundwork for further work. Understanding the 
confounding factors and limitations of these probes and reagents can influence more intelligent 
experimental designs; additionally, based on the work with clonal population in Chapter V, some 
of these results may very well be averaged out due to the population level responses being 
measured. It would be interesting to see if subclones with differential responses to PLX4720 
engender differential 1) ROS formation, or 2) detoxification. 
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APPENDICES 
 
 
Appendix A: Media Formulations (Comparisons). Table highlighting a few of the prominent 
nutrients in the media utilized within this thesis. All values are in mM concentrations. 
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Appendix B: Growth Curves and Population Doublings of Melanoma Cell Lines In the 
Presence of Oligomycin (Part 1/2). Representative experiments of BRAF-mutated cell lines 
treated with oligomycin (first set of six cell lines). The proliferation was log-2 normalized and 
plotted as population doubling (y-axis) over time (x-axis, in hours). The concentrations of 
oligomycin started at 4 µM, going down 4-fold to zero control (ethanol). Therefore, the doses 
used are as follows: 4000 nM, 1000 nM, 250 nM, 62.5 nM, 15.625 nM, 3.9 nM, 0.97 nM, 0.244 
nM, 0.06 nM, and ethanol control. For graph clarity, some of the concentrations are not shown, 
in order to eliminate crowding of the graph curves. Data shown are from a single experiment 
with technical duplicates; experiment has been repeated at least twice with similar results. Error 
bars are standard deviation. Additionally, for perspective about the dosing: 1 µM is needed to 
adequately inhibit oxygen consumption in our Seahorse assays. 
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Appendix C: Growth Curves and Population Doublings of Melanoma Cell Lines In the 
Presence of Oligomycin (Part 2/2). Representative experiments of BRAF-mutated cell lines 
treated with oligomycin. The proliferation was log-2 normalized and plotted as population 
doubling (y-axis) over time (x-axis, in hours). The concentrations of oligomycin started at 4 µM, 
going down 4-fold to zero control (ethanol). Therefore, the doses used are as follows: 4000 nM, 
1000 nM, 250 nM, 62.5 nM, 15.625 nM, 3.9 nM, 0.97 nM, 0.244 nM, 0.06 nM, and ethanol 
control. For graph clarity, some of the concentrations are not shown, in order to eliminate 
crowding of the graph curves. Data shown are from a single experiment with technical 
duplicates; experiment has been repeated at least twice with similar results. Error bars are 
standard deviation. Additionally, for perspective about the dosing: 1 µM is needed to adequately 
inhibit oxygen consumption in our Seahorse assays. 
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Appendix D: Variability of Response to Oxamic Acid in Melanoma Cell Lines. Proliferative, 
dose-response spectrum of IC50’s for Oxamic acid based on DIP rate. The dose-response curves 
are generated using a 2-fold dilution of Oxamic acid from 50 mM down to zero (PBS). The 
proliferative rates are calculated using the slope of the log2-normalized population curve after 48 
hours. Data shown are from 3+ experiments and 95% confidence intervals are the shaded 
regions.
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